Kraton Corp Form 10-Q October 27, 2016

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF \circ_{1934}

For the quarterly period ended September 30, 2016

..TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number 001-34581

Kraton Corporation

(Exact Name of Registrant as Specified in its Charter)

Delaware 20-0411521 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

15710 John F. Kennedy Blvd.

Suite 300 281-504-4700

Houston, TX 77032

(Address of principal executive offices, including zip code) (Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes \circ No "Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T ($^{\circ}$ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes \circ No "

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Securities Exchange Act. (Check one):

Large accelerated filer: ý Accelerated filer:

Non-accelerated filer: "Smaller reporting company:"

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes "No ý

Number of shares of Kraton Corporation Common Stock, \$0.01 par value, outstanding as of October 24, 2016: 30,916,346.

Index to Quarterly Report on Form 10-Q for Quarter Ended September 30, 2016

PART I.	FINANCIAL INFORMATION	Page
	Report of KPMG LLP, Independent Registered Public Accounting Firm	<u>6</u>
Item 1	Condensed Consolidated Financial Statements (Unaudited)	7
	Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015	<u>7</u>
	Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016 and 2015	<u>8</u>
	Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2016 and 2015	9
	Condensed Consolidated Statements of Changes in Equity for the nine months ended September 30, 2016 and 2015	<u>10</u>
	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015	<u>11</u>
	Notes to the Condensed Consolidated Financial Statements	<u>12</u>
Item 2	Management's Discussion and Analysis of Financial Condition and Results of Operations	<u>49</u>
Item 3	Quantitative and Qualitative Disclosures About Market Risk	<u>67</u>
Item 4	Controls and Procedures	<u>67</u>
PART II.	OTHER INFORMATION	
Item 1	<u>Legal Proceedings</u>	<u>67</u>
Item 1A	Risk Factors	<u>67</u>
Item 6	Exhibits	<u>68</u>
	Signatures	<u>69</u>
2		

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Some of the statements in this Quarterly Report on Form 10-Q under the headings "Condensed Consolidated Financial Statements" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. We may also make written or oral forward-looking statements in our periodic reports on Forms 10-K, 10-Q and 8-K, in press releases and other written materials and in oral statements made by our officers, directors or employees to third parties. Statements that are not historical facts, including statements about our beliefs and expectations, are forward-looking statements. Forward-looking statements are often characterized by the use of words such as "outlook," "believes," "estimates," "expects," "projects," "may," "intends," "plans" or "anticipates," or by discussions of strategy, plans or intentions; anticipated benefits of or performance of our products; beliefs regarding opportunities for new, differentiated applications and other innovations; adequacy of cash flows to fund our working capital requirements; our investment in the joint venture with Formosa Petrochemical Corporation ("FPCC"); our expectations regarding indebtedness to be incurred by our joint venture with FPCC; expected synergies and cost savings associated with the acquisition of Arizona Chemical Holdings Corporation (now known as AZ Chem Holdings LP, "Arizona Chemical"); debt payments, interest payments, benefit plan contributions, and income tax obligations; our anticipated 2016 capital expenditures, health, safety and environmental and infrastructure and maintenance projects, projects to optimize the production capabilities of our manufacturing assets and to support our innovation platform; our ability to fully access our senior secured credit facilities; expectations regarding our counterparties' ability to perform, including with respect to trade receivables; estimates regarding the tax expense of repatriating certain cash and short-term investments related to foreign operations; expectations regarding differentiated applications; our ability to realize certain deferred tax assets and our beliefs with respect to tax positions; expectations regarding our full year effective tax rate; estimates related to the useful lives of certain assets for tax purposes; expectations regarding our pension contributions for fiscal year 2016; estimates or expectations related to monomer costs, ending inventory levels and related estimated charges; the outcome and financial impact of legal proceedings; and projections regarding environmental costs and capital expenditures and related operational savings. Such forward-looking statements involve known and unknown risks, uncertainties, assumptions and other important factors that could cause the actual results, performance or our achievements, or industry results, to differ materially from historical results, any future results, or performance or achievements expressed or implied by such forward-looking statements. There are a number of risks and uncertainties that could cause our actual results to differ materially from the forward-looking statements contained in this report. Further description of these risks and uncertainties and other important factors are set forth in this report, in our latest Annual Report on Form 10-K, including but not limited to "Part I, Item 1A. Risk Factors" and "Part II, Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations" therein, and in our other filings with the Securities and Exchange Commission, and include, but are not limited to, risks related to: failure to successfully integrate Arizona Chemical in the expected time frame, which may adversely affect our future results, including the realization of anticipated cost synergies and the incurrence of additional and/or unexpected costs in order to realize them;

failure to successfully achieve the expected synergies or significant delays in achieving such expected synergies in connection with the Arizona Chemical Acquisition;

our substantial indebtedness, which could adversely affect our financial condition and prevent us from fulfilling our obligations under our current and future indebtedness;

we may incur additional indebtedness or we may pay dividends in the future, which could further exacerbate the risks associated with our substantial financial leverage;

our current and future debt instruments may impose significant operating and financial restrictions on us and affect our ability to access liquidity;

to service our indebtedness, we will require a significant amount of cash;

our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly;

conditions in the global economy and capital markets;

the failure of our raw materials suppliers to perform their obligations under long-term supply agreements, or our inability to replace or renew these agreements when they expire;

limitations in the availability of raw materials we need to produce our products in the amounts or at the prices necessary for us to effectively and profitably operate our business;

the promotion of the use of energy from renewable resources and similar legislation in the United States and elsewhere may incentivize the use of crude tall oil ("CTO") as a feedstock for production of alternative fuels, reducing the availability of CTO in the amounts or prices necessary for our business;

significant fluctuations in raw material costs may result in volatility in our quarterly operating results and impact the market price of our common stock;

our reliance on LyondellBasell Industries for the provision of significant operating and other services;

competition from other producers of styrenic block copolymers and from producers of products that can be substituted for our products;

our ability to produce and commercialize technological innovations;

our ability to protect our intellectual property, on which our business is substantially dependent;

the possibility that our products infringe upon the intellectual property rights of others;

a major failure of our information systems, which could harm our business;

seasonality in our business may affect our quarterly operating results;

the inherently hazardous nature of chemical manufacturing;

product liability claims and other lawsuits arising from environmental damage, personal injuries, other damages associated with chemical manufacturing or our products;

political, economic and local business risks in the various countries in which we operate;

health, safety and environmental laws, including laws that govern our employees' exposure to chemicals deemed harmful to humans;

regulation of our company or our customers, which could affect the demand for our products or result in increased compliance and other costs;

customs, international trade, export control, antitrust, zoning and occupancy and labor and employment laws that could require us to modify our current business practices and incur increased costs;

fluctuations in currency exchange rates:

we may have additional tax liabilities;

our formation of a joint venture to expand hydrogenated styrenic block copolymers capacity in Asia;

our relationship with our employees;

loss of key personnel or our inability to attract and retain new qualified personnel;

the fact that we generally do not enter into long-term contracts with our customers;

a decrease in the fair value of our pension assets could require us to materially increase future funding requirements of the pension plan;

domestic or international natural disasters or terrorist attacks may disrupt our operations;

Delaware law and some provisions of our organizational documents that make a takeover of our company more difficult;

our expectation that we will not pay dividends for the foreseeable future; and

we are a holding company with nominal net worth and will depend on dividends and distributions from our subsidiaries to pay any dividends.

There may be other factors of which we are currently unaware or that we deem immaterial that may cause our actual results to differ materially from the expectations we express in our forward-looking statements. Although we believe the assumptions underlying our forward-looking statements are reasonable, any of these assumptions, and, therefore, also the forward-looking statements based on these assumptions could themselves prove to be inaccurate.

Forward-looking statements are based on current plans, estimates, assumptions and projections, and therefore you should not place undue reliance on them. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update them publicly in light of new information or future events.

Presentation of Financial Statements

The terms "Kraton," "our company," "we," "our," "ours" and "us" as used in this report refer collectively to Kraton Corporation formerly known as Kraton Performance Polymers, Inc., and its consolidated subsidiaries. Furthermore, these references relate to the combined company including both the legacy Kraton and legacy Arizona Chemical businesses. This Form 10-Q includes financial statements and related notes that present the condensed consolidated financial position, results of operations, comprehensive income (loss), and cash flows of Kraton. Kraton Corporation is a holding company whose only material asset is its investment in its wholly owned subsidiary, Kraton Polymers LLC. Kraton Polymers LLC and its subsidiaries own all of our consolidated operating assets.

Report of Independent Registered Public Accounting Firm

The Board of Directors and Stockholders

Kraton Corporation:

We have reviewed the accompanying condensed consolidated balance sheet of Kraton Corporation and subsidiaries (the "Company") as of September 30, 2016, the related condensed consolidated statements of operations, and comprehensive income (loss), for the three-month and nine-month periods ended September 30, 2016 and 2015, and the related condensed consolidated statements of changes in equity, and cash flows for the nine-month periods ended September 30, 2016 and 2015. These condensed consolidated financial statements are the responsibility of the Company's management.

We conducted our reviews in accordance with the standards of the Public Company Accounting Oversight Board (United States). A review of interim financial information consists principally of applying analytical procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit conducted in accordance with the standards of the Public Company Accounting Oversight Board (United States), the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our reviews, we are not aware of any material modifications that should be made to the condensed consolidated financial statements referred to above for them to be in conformity with U.S. generally accepted accounting principles.

We have previously audited, in accordance with standards of the Public Company Accounting Oversight Board (United States), the consolidated balance sheet of Kraton Corporation and subsidiaries as of December 31, 2015, and the related consolidated statements of operations, comprehensive income (loss), changes in equity, and cash flows for the year then ended (not presented herein); and in our report dated February 24, 2016, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2015 is fairly stated, in all material respects, in relation to the consolidated balance sheet from which it has been derived.

/s/ KPMG LLP Houston, Texas October 27, 2016

PART I. FINANCIAL INFORMATION

Item 1. Condensed Consolidated Financial Statements.

KRATON CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands, except par value)

	September 30 2016 (unaudited)	, December 31, 2015
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 143,548	\$70,049
Receivables, net of allowances of \$847 and \$244	209,867	105,089
Inventories of products	321,845	264,107
Inventories of materials and supplies	20,717	12,138
Other current assets	68,134	29,956
Total current assets	764,111	481,339
Property, plant, and equipment, less accumulated depreciation of \$420,907 and \$382,15	7 905,117	517,673
Goodwill	753,928	
Intangible assets, less accumulated amortization of \$135,361 and \$100,093	451,576	41,602
Investment in unconsolidated joint venture	11,608	11,628
Debt issuance costs	3,803	1,337
Deferred income taxes	5,218	3,867
Other long-term assets	23,332	21,789
Total assets	\$2,918,693	\$1,079,235
LIABILITIES AND EQUITY		
Current liabilities:		
Current portion of long-term debt	\$23,135	\$141
Accounts payable-trade	134,560	59,337
Other payables and accruals	157,330	91,011
Due to related party	14,907	14,101
Total current liabilities	329,932	164,590
Long-term debt, net of current portion	1,698,952	415,591
Deferred income taxes	213,776	9,070
Other long-term liabilities	141,305	96,992
Total liabilities	2,383,965	686,243
Commitments and contingencies (note 11)	, ,	,
Equity:		
Kraton stockholders' equity:		
Preferred stock, \$0.01 par value; 100,000 shares authorized; none issued	_	
Common stock, \$0.01 par value; 500,000 shares authorized; 30,916 shares issued and		
outstanding at September 30, 2016; 30,569 shares issued and outstanding at December	309	306
31, 2015		
Additional paid in capital	358,798	349,871
Retained earnings	258,179	147,131
Accumulated other comprehensive loss	•	(138,568)
Total Kraton stockholders' equity	500,675	358,740
Total Islaton stockholders equity	500,015	330,170

Noncontrolling interest 34,053 34,252 Total equity 534,728 392,992 Total liabilities and equity \$2,918,693 \$1,079,235

See Notes to Condensed Consolidated Financial Statements

KRATON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except per share data)

	Three Mor	nths Ended	Nine Month	s Ended
	September	30,	September 3	0,
	2016	2015	2016	2015
Revenue	\$454,143	\$269,012	\$1,328,715	\$786,349
Cost of goods sold	318,887	201,202	967,744	624,542
Gross profit	135,256	67,810	360,971	161,807
Operating expenses:				
Research and development	9,693	7,597	30,383	23,345
Selling, general, and administrative	42,769	26,917	135,845	77,488
Depreciation and amortization	31,977	16,145	93,913	46,852
Operating income	50,817	17,151	100,830	14,122
Disposition and exit of business activities	_	_	40,001	_
Loss on extinguishment of debt	_	_	(13,423)	· —
Earnings of unconsolidated joint venture	94	95	274	273
Interest expense, net	(33,870)	(6,151)	(101,450)	(17,975)
Income (loss) before income taxes	17,041	11,095	26,232	(3,580)
Income tax benefit (expense)	(2,198)	(3,076)	83,024	(4,135)
Consolidated net income (loss)	14,843	8,019	109,256	(7,715)
Net loss attributable to noncontrolling interest	717	427	1,792	1,141
Net income (loss) attributable to Kraton	\$15,560	\$8,446	\$111,048	\$(6,574)
Earnings (loss) per common share:				
Basic	\$0.50	\$0.27	\$3.60	\$(0.21)
Diluted	\$0.49	\$0.27	\$3.56	\$(0.21)
Weighted average common shares outstanding:				
Basic	30,221	30,503	30,137	30,779
Diluted	30,783	30,849	30,557	30,779

See Notes to Condensed Consolidated Financial Statements

KRATON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) (Unaudited) (In thousands)

	Three Mo Ended Se 30,		Nine Mont September	
	2016	2015	2016	2015
Net income (loss) attributable to Kraton	\$15,560	\$8,446	\$111,048	\$(6,574)
Other comprehensive income (loss):				
Foreign currency translation adjustments, net of tax of \$0	3,994	(14,972)	27,311	(38,787)
Unrealized loss on cash flow hedges, net of tax benefit of \$27 and \$2,737 for 2016 respectively	(48)	_	(5,354)	_
Other comprehensive income (loss), net of tax	3,946	(14,972)	21,957	(38,787)
Comprehensive income (loss) attributable to Kraton	19,506	(6,526)	133,005	(45,361)
Comprehensive income (loss) attributable to noncontrolling interest	339	(2,717)	(199)	(2,579)
Consolidated comprehensive income (loss)	\$19,845	\$(9,243)	\$132,806	\$(47,940)

See Notes to Condensed Consolidated Financial Statements

KRATON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (Unaudited) (In thousands)

	Commo Stock	Additional Paid in Capital	Retained Earnings	Accumulated Other Comprehensiv Loss	Total Kraton Stockholders Equity	Noncontrolli	n F otal Equity
Balance at December 31, 2014	\$ 318	\$361,342	\$168,041	\$ (99,218)	\$ 430,483	\$ 37,668	\$468,151
Net loss			(6,574)	_	(6,574)	(1,141)	(7,715)
Other comprehensive loss		_	_	(38,787)	(38,787)	(1,438)	(40,225)
Retired treasury stock from employee tax withholdings		(570)	_	_	(570)		(570)
Retired treasury stock from share repurchases	(16)	(20,930)	(10,375)	_	(31,321)		(31,321)
Exercise of stock options	1	1,021	_		1,022		1,022
Non-cash compensation related to equity awards	1 2	6,599	_	_	6,601	_	6,601
Balance at September 30, 2015	\$ 305	\$347,462	\$151,092	\$ (138,005)	\$ 360,854	\$ 35,089	\$395,943
Balance at December 31, 2015 Net income (loss) Other comprehensive income	\$ 306 	\$349,871 — —	\$147,131 111,048	\$ (138,568) 21,957	\$ 358,740 111,048 21,957	\$ 34,252 (1,792) 1,593	\$392,992 109,256 23,550
Retired treasury stock from employee tax withholdings	(1)	(966)	_	_	(967)	· —	(967)
Exercise of stock options	1	2,624		_	2,625	_	2,625
Non-cash compensation related to equity awards	13	7,269	_	_	7,272	_	7,272
Balance at September 30, 2016	\$ 309	\$358,798	\$258,179	\$ (116,611)	\$ 500,675	\$ 34,053	\$534,728

See Notes to Condensed Consolidated Financial Statements 10

KRATON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited) (In thousands)

(In thousands)		
	Nine Mon	
	September	
	2016	2015
CASH FLOWS FROM OPERATING ACTIVITIES		
Consolidated net income (loss)	\$109,256	\$(7,715)
Adjustments to reconcile consolidated net income (loss) to net cash provided by operating		
activities:		
Depreciation and amortization	93,913	46,852
Amortization of debt premium and original issue discount	4,893	(130)
Amortization of debt issuance costs	5,343	1,668
(Gain) loss on disposal of property, plant, and equipment	452	(60)
Disposition and exit of business activities	(40,001) —
Loss on extinguishment of debt	13,423	
Earnings from unconsolidated joint venture, net of dividends received	136	90
Deferred income tax benefit	(4,343	(2,270)
Release of valuation allowance	(86,631) —
Share-based compensation	7,272	6,601
Decrease (increase) in:		
Accounts receivable	(18,114	(9,693)
Inventories of products, materials, and supplies	44,035	50,462
Other assets	(3,044) (2,022)
Increase (decrease) in:		
Accounts payable-trade	(2,981	(2,988)
Other payables and accruals	(401	1,548
Other long-term liabilities	4,631	•
Due to related party	(1,710	(2,306)
Net cash provided by operating activities	126,129	81,573
CASH FLOWS FROM INVESTING ACTIVITIES		
Kraton purchase of property, plant, and equipment	(62,885)	(42,384)
KFPC purchase of property, plant, and equipment	(16,995)	(46,097)
Purchase of software and other intangibles	(4,691	(1,763)
Acquisition, net of cash acquired	(1,312,105	5 —
Sale of assets	72,803	
Net cash used in investing activities	(1,323,873	3 (90,244)
CASH FLOWS FROM FINANCING ACTIVITIES		
Proceeds from debt	1,782,965	30,000
Repayments of debt	(480,133)	(30,000)
KFPC proceeds from debt	24,368	55,622
Capital lease payments	(105) (99)
Purchase of treasury stock	(967	(31,891)
Proceeds from the exercise of stock options	2,625	1,022
Settlement of interest rate swap	(5,155) —
Debt issuance costs	(57,646) —
Net cash provided by financing activities	1,265,952	24,654
Effect of exchange rate differences on cash	5,291	(6,002)

Net increase in cash and cash equivalents Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period	73,499 70,049 \$143,548	9,981 53,818 \$63,799
Supplemental disclosures:		
Cash paid during the period for income taxes, net of refunds received	\$7,788	\$5,435
Cash paid during the period for interest, net of capitalized interest	\$56,972	\$21,690
Capitalized interest	\$4,022	\$3,342
Supplemental non-cash disclosures:		
Property, plant, and equipment accruals	\$30,494	\$16,023
Asset acquired through capital lease	\$	\$681

See Notes to Condensed Consolidated Financial Statements

KRATON CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Unaudited)

1. General

Description of our Business. We are a leading global specialty chemicals company that manufactures styrenic block copolymers ("SBCs") and other engineered polymers. Effective with the January 6, 2016 acquisition of Arizona Chemical (the "Arizona Chemical Acquisition"), we are now also a leading global producer of value-added specialty products primarily derived from pine wood pulping co-products. The operating results of Arizona Chemical have been included in these financial statements since January 6, 2016, the date of the Arizona Chemical Acquisition.

SBCs are highly-engineered synthetic elastomers, which we invented and commercialized over 50 years ago. We developed the first unhydrogenated styrenic block copolymers ("USBC") in 1964 and the first hydrogenated styrenic block copolymers ("HSBC") in the late 1960s. Our SBCs enhance the performance of numerous products by imparting greater flexibility, resilience, strength, durability, and processability, and are used in a wide range of applications, including adhesives, coatings, consumer and personal care products, sealants, lubricants, medical, packaging, automotive, and paving and roofing products. We also manufacture and sell isoprene rubber ("IR") and isoprene rubber latex ("IRL") which are non-SBC products primarily used in applications such as medical products, personal care, adhesives, tackifiers, paints, and coatings.

We also refine and further upgrade two primary feedstocks, crude tall oil ("CTO") and crude sulfate turpentine ("CST"), into value-added specialty chemicals. Our pine-based specialty products are sold into adhesive, road and construction, and tire markets, and we produce and sell a broad range of chemical intermediates into markets that include fuel additives, oilfield chemicals, coatings, metalworking fluids and lubricants, inks, flavors and fragrances, and mining. References in this report to "Kraton," "our company," "we," "our," "ours" and "us" as used in this report refer collectively to Kraton Corporation and its consolidated subsidiaries. Furthermore, these references relate to the combined company including both the legacy Kraton and legacy Arizona Chemical businesses, except for historical financial information prior to the January 6, 2016 Arizona Chemical Acquisition.

Basis of Presentation. The accompanying unaudited Condensed Consolidated Financial Statements presented herein are for us and our consolidated subsidiaries, each of which is a wholly-owned subsidiary, except our 50% investment in our joint venture, Kraton Formosa Polymers Corporation ("KFPC"), located in Mailiao, Taiwan. KFPC is a variable interest entity for which we have determined that we are the primary beneficiary and, therefore, have consolidated into our financial statements. Our 50% investment in our joint venture located in Kashima, Japan, is accounted for under the equity method of accounting. All significant intercompany transactions have been eliminated. These interim financial statements should be read in conjunction with the consolidated financial statements included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 and reflect all normal recurring adjustments that are, in the opinion of management, necessary to present fairly our results of operations and financial position. Amounts reported in our Condensed Consolidated Statements of Operations are not necessarily indicative of amounts expected for the respective annual periods or any other interim period, in particular due to the effect of seasonal changes and weather conditions that typically affect our sales into paving, roadmarking, roofing and construction applications. In particular, sales volumes into these applications are generally higher in the second and third quarter of the calendar year as warm and dry weather is more conducive to paving and roofing activity.

Significant Accounting Policies. Our significant accounting policies have been disclosed in Note 1 Description of Business, Basis of Presentation, and Significant Accounting Policies in our most recent Annual Report on Form 10-K. In connection with the Arizona Chemical Acquisition, we updated our accounting policies as follows.

Goodwill and Other Intangible Assets. We record goodwill when the purchase price of an acquired business exceeds the fair value of the net identifiable assets acquired. Goodwill and intangible assets are allocated to the reporting unit level based on the estimated fair value at the date of the Arizona Chemical Acquisition.

Goodwill and other indefinite-lived intangible assets are tested for impairment at the reporting unit level annually or more frequently as deemed necessary. Our annual measurement date for testing impairment is October 1st. The impairment test includes a comparison of the carrying value of net assets of our reporting units, including goodwill, with their estimated fair values. If the carrying value exceeds the estimated fair value, an impairment charge is

recognized in the period in which the review is performed.

There have been no other changes to the accounting policies as disclosed in our most recent Annual Report on Form 10-K. The accompanying unaudited Condensed Consolidated Financial Statements we present in this report have been prepared in accordance with our policies.

Use of Estimates. The preparation of the Condensed Consolidated Financial Statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the Condensed Consolidated Financial Statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Significant items subject to such estimates and assumptions include

the useful lives of long-lived assets;

estimates of fair value for assets acquired and liabilities assumed in business combinations;

allowances for doubtful accounts and sales returns;

the valuation of derivatives, deferred tax assets, property, plant and equipment, intangible assets, inventory, investments, and share-based compensation; and

liabilities for employee benefit obligations, environmental matters, asset retirement obligations ("ARO"), income tax uncertainties and other contingencies.

Income Tax in Interim Periods. We conduct operations in separate legal entities in different jurisdictions. As a result, income tax amounts are reflected in these Condensed Consolidated Financial Statements for each of those jurisdictions. Tax laws and tax rates vary substantially in these jurisdictions and are subject to change based on the political and economic climate in those countries. We file our tax returns in accordance with our interpretations of each jurisdiction's tax laws. We record our tax provision or benefit on an interim basis using the estimated annual effective tax rate. This rate is applied to the current period ordinary income or loss to determine the income tax provision or benefit allocated to the interim period.

Losses from jurisdictions for which no benefit can be realized and the income tax effects of unusual and infrequent items are excluded from the estimated annual effective tax rate. Valuation allowances are provided against the future tax benefits that arise from the losses in jurisdictions for which no benefit can be realized. The effects of unusual and infrequent items are recognized in the impacted interim period as discrete items.

The estimated annual effective tax rate may be significantly affected by nondeductible expenses and by our projected earnings mix by tax jurisdiction. Adjustments to the estimated annual effective income tax rate are recognized in the period during which such estimates are revised.

We have established valuation allowances against a variety of deferred tax assets, including net operating loss carryforwards, foreign tax credits and other income tax credits. Valuation allowances take into consideration our expected ability to realize these deferred tax assets and reduce the value of such assets to the amount that is deemed more likely than not to be recoverable. Our ability to realize these deferred tax assets is dependent on achieving our forecast of future taxable operating income over an extended period of time. We review our forecast in relation to actual results and expected trends on a quarterly basis. If we fail to achieve our operating income targets, we may change our assessment regarding the recoverability of our net deferred tax assets and such change could result in a valuation allowance being recorded against some or all of our net deferred tax assets. A change in our valuation allowance would impact our income tax benefit (expense) and our stockholders' equity and could have a significant impact on our results of operations or financial condition in future periods.

2. New Accounting Pronouncements

Adoption of Accounting Standards

We have implemented all new accounting pronouncements that are in effect and that management believes would materially affect our financial statements.

In February 2015, the Financial Accounting Standards Board (the "FASB") issued Accounting Standards Update ("ASU") No. 2015-02, Consolidation (Topic 810): Amendments to the Consolidation Analysis. This standard changes the consolidation analysis currently required under U.S. generally accepted accounting principles ("GAAP"). This ASU modifies the process used to evaluate whether limited partnerships and similar entities are variable interest entities ("VIEs") or voting interest entities; affects the analysis performed by reporting entities regarding VIEs, particularly those with fee arrangements and related party relationships; and provides a scope exception for certain investment funds. The amendments in this update are effective for annual and interim periods beginning after December 15, 2015

and early adoption is permitted. We adopted this standard in the first quarter of 2016 and there was no material impact on our consolidated financial statements.

In April 2015, the FASB issued ASU No. 2015-03, Interest-Imputation of Interest. This standard requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of such debt liability. In adopting ASU 2015-03, companies must apply the guidance on a retrospective basis. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. We adopted this standard in the first quarter of 2016. As a result of retrospective application, the adoption of this standard resulted in reductions of approximately \$1.3 million, \$12.1 million, and \$13.5 million of other current assets, debt issuance costs, and

long-term debt, respectively, as of December 31, 2015. Furthermore, we had a material change in debt issuance costs in association with the financing for the Arizona Chemical Acquisition in the first quarter of 2016. See Note 8 Long Term Debt for further information about debt issuance costs as of September 30, 2016.

In September 2015, the FASB issued ASU No. 2015-16, Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments. This standard requires that an acquirer recognize adjustments to provisional amounts that are identified during the measurement period in the reporting period in which the adjustment amounts are determined. This includes recording in the reporting period the effect on earnings of changes in depreciation, amortization, or other income effects as a result of the change to the provisional amounts as if the accounting had been completed at the acquisition date. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2015. We adopted this standard in the first quarter of 2016 and will apply such guidance on our recording of the Arizona Chemical Acquisition. See Note 3 Acquisition of Arizona Chemical for further information about the measurement period for this acquisition.

New Accounting Standards

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers, updated by ASU No. 2015-14 Deferral of the Effective Date, which provides a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and will supersede most current revenue recognition guidance. In August 2015, the effective date for the standard was deferred by one year and the standard is now effective for public entities for annual and interim periods beginning after December 15, 2017. Early adoption is permitted based on the original effective date. Our evaluation of this standard is currently ongoing and therefore, the effects of this standard on our financial position, results of operations and cash flows are not yet known.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. This standard changes the measurement principle for inventory from the lower of cost or market to the lower of cost or net realizable value. ASU 2015-11 defines net realizable value as the estimated selling price in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance must be applied on a prospective basis and is effective for periods beginning after December 15, 2016, with early adoption permitted. We have evaluated this standard and we do not expect there to be a material impact on our consolidated financial statements.

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842). This standard requires that an entity must recognize in the statement of financial position a liability to make lease payments (the lease liability) and a right-of-use asset representing its right to use the underlying asset for the lease term. For leases with a term of twelve months or less, a lessee is permitted to make an accounting policy election by class of underlying asset not to recognize lease assets and liabilities. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2018 and early adoption is permitted. Our evaluation of this standard is currently ongoing and therefore, the effects of this standard on our financial position, results of operations and cash flows are not yet known.

In March 2016, the FASB issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 817). The ASU changes seven aspects of the accounting for share-based payment award transactions, including: (1) accounting for income taxes; (2) classification of excess tax benefits on the statement of cash flows; (3) forfeitures; (4) minimum statutory tax withholding requirements; (5) classification of employee taxes paid on the statement of cash flows when an employer withholds shares for tax-withholding purposes; (6) practical expedient - expected term (nonpublic only); (7) intrinsic value (nonpublic only). The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, and early adoption is permitted. Our evaluation of this standard is currently ongoing and therefore, the effects of this standard on our financial position, results of operations and cash flows are not yet known.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230). The ASU addresses eight specific cash flow issues with the objective of reducing the existing diversity in practice. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2017, and early adoption is permitted. Our evaluation of this standard is currently ongoing and therefore, the effects of this standard on our financial position, results of operations and cash flows are not yet known.

3. Acquisition of Arizona Chemical

On January 6, 2016, we acquired all of the capital stock of Arizona Chemical for a purchase price of \$1,361.9 million. In accordance with the sale and purchase agreement, we finalized the purchase price with the sellers and received \$5.1 million of cash during the nine months ended September 30, 2016.

The \$1,361.9 million purchase price for the Arizona Chemical Acquisition, the cash tender offer and redemption of all outstanding 6.75% senior notes due 2019, and the related acquisition and financing expenses for the Arizona Chemical Acquisition were funded through the following transactions:

A \$1,350.0 million six-year senior secured first lien term loan facility,

A private offering of \$440.0 million in aggregate principal amount of 10.5% senior notes due 2023, and

An amended and restated \$250.0 million five-year asset-based revolving credit facility.

Our previously outstanding indebtedness under the 6.75% senior notes due 2019 and the former senior secured credit facilities were satisfied and canceled on January 6, 2016. See Note 8 Long-Term Debt to the Condensed Consolidated Financial Statements for a further description of the debt issued to finance the Arizona Chemical Acquisition.

We have accounted for the Arizona Chemical Acquisition using the purchase method of accounting for business combinations. Accordingly, the purchase price has been allocated to the underlying assets and liabilities in proportion to their respective fair values. The excess of the purchase price over the estimated fair value of the net assets acquired has been recorded as goodwill. Following the close of the Arizona Chemical Acquisition, the operating results of Arizona Chemical are reported as a separate operating segment, "Chemical segment". See Note 13 Industry Segments and Foreign Operations for further information.

For the three and nine months ended September 30, 2016, respectively, we recognized \$6.6 million and \$25.1 million of transaction and integration related costs which are included in selling, general, and administrative expenses in the Condensed Consolidated Statements of Operations.

The following table summarizes the preliminary purchase price allocation for the Arizona Chemical Acquisition. This allocation is based on management's estimates, judgments, and assumptions which are subject to change upon final valuation and should be treated as preliminary values. We have not finalized the allocation of the purchase consideration to the estimated fair value of (1) property, plant, and equipment; (2) intangible assets; (3) deferred income taxes and uncertain tax positions, and we are continuing to review all of the working capital acquired.

Weighted Average Amortization Period Fair Value

		(In
		thousands)
Cash		\$49,835
Inventories ⁽¹⁾		122,305
Litigation asset		94,204
Accounts receivable and other current	assets	118,394
Property, plant, and equipment		350,584
Intangible assets:(2)	12.9 years	
Contractual Agreements	12 years	260,400
Customer Relationships	17 years	25,000
Technology	16 years	100,000
Trade Name	10 years	50,000
Software	3-5 years	4,140
Goodwill ⁽³⁾		753,874
Other long-term assets		3,662
Current liabilities		(128,070)
Income tax liabilities		(301,285)
Leases		(422)
Other long-term liabilities		(140,681)
Purchase price		1,361,940
Cash		49,835
Purchase price, net of cash acquired		\$1,312,105

⁽¹⁾ An adjustment of approximately \$24.7 million was recorded to reflect Arizona Chemical's inventories at fair value and increased cost of sales by the same amount for the nine months ended September 30, 2016.

Aggregate amortization expense was approximately \$26.8 million from January 6, 2016 through September 30,

- (2)2016. Estimated amortization expense 2016—\$35.1 million; 2017—\$35.6 million; 2018—\$35.4 million; 2019—\$35.4 million; and 2020—\$34.4 million.
 - During the third quarter of 2016, we adjusted the preliminary purchase price allocation based on further review of the assets acquired and liabilities assumed. Based on additional analysis of the underlying contracts, we decreased
- (3) the customer relationship intangible asset by \$80.0 million and increased the contractual agreement intangible asset by \$70.0 million. The remaining adjustments related to various working capital accounts that required fair value modifications, primarily related to current liabilities and income tax liabilities. Each of these measurement period adjustments correspondingly increased goodwill.

Goodwill has been calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. See Note 13 Industry Segments and Foreign Operations for further information regarding our reportable segments. Goodwill recognized as a result of the acquisition is not deductible for tax purposes.

We are continuing to evaluate the option to apply pushdown accounting, which would result in recording the various assets acquired and liabilities assumed at their fair value at the date of the Arizona Chemical Acquisition in each domestic and foreign legal entity of Arizona Chemical for financial reporting purposes.

The fair value of acquired identifiable intangible assets was determined using the "income approach" on an individual project basis. In performing these valuations, the key underlying probability-adjusted assumptions of the discounted cash flows were projected revenues, gross margin expectations, and operating cost estimates, when appropriate. The valuations were based on the information that was available as of the acquisition date and the expectations and assumptions that have been deemed reasonable by the Company's management. There are inherent uncertainties and management judgment required in these determinations. The fair value measurements of the assets acquired and liabilities assumed were based on valuations involving significant unobservable inputs, or Level 3 in the fair value hierarchy.

The purchase price of Arizona Chemical exceeded the net acquisition-date amounts of the identifiable assets acquired and the liabilities assumed. Cash flows used to determine the purchase price included strategic and synergistic benefits specific to the Company, which resulted in a purchase price in excess of the fair value of identifiable net assets. The purchase price also included the fair values of other assets that were not identifiable, not separately recognizable under accounting rules (e.g., assembled workforce) or of immaterial value in addition to a going-concern element that represents the Company's ability to earn a higher rate of return on the group of assets than would be expected on the separate assets as determined during the valuation process.

Arizona Chemical contributed revenue and net income of \$542.6 million and \$37.1 million, respectively, to the consolidated operating results of Kraton for the period from January 6, 2016 through September 30, 2016. The following unaudited pro forma information presents consolidated information as if the Arizona Chemical Acquisition had occurred on January 1, 2015:

•	Three Months Ended September 30,		Nine Months Ended September 30,	
	2016	2015	2016	2015
	(In thousa	nds, excep	t per share d	ata)
Revenue	\$454,143	\$476,493	\$1,328,715	\$1,407,306
Net income (loss) attributable to Kraton	\$15,560	\$11,406	\$135,840	\$10,715
Earnings per share				
Basic	\$0.50	\$0.37	\$4.41	\$0.34
Diluted	\$0.49	\$0.36	\$4.35	\$0.34

The unaudited pro forma information presented above is for information purposes only and is not necessarily indicative of the operating results that would have occurred had the Arizona Chemical Acquisition been consummated at the beginning of the period, nor is it necessarily indicative of future operating results. The unaudited pro forma amounts above have been calculated after applying Kraton's accounting policies and adjusting the Arizona Chemical

results to reflect (1) the additional depreciation and amortization that would have been charged assuming the fair value adjustments to property, plant, and equipment and intangible assets had been applied from January 1, 2015; (2) the elimination of historical interest expense for Arizona Chemical as this debt was paid off by the previous owners; (3) the additional interest expense resulting from the debt issued to fund the Arizona Chemical Acquisition; (4) the elimination of transaction-related costs; (5) the effect of purchase price accounting on inventory valuation; and (6) an adjustment to tax-effect the aforementioned unaudited pro forma adjustments using an estimated aggregate statutory income tax rate of the jurisdiction to which the above adjustments relate. The unaudited pro forma amounts do not include any potential synergies, cost savings or other expected benefits of the Arizona Chemical Acquisition.

4. Disposition and Exit of Business Activities

Exit of NEXARTM

In June 2016, we exited our NEXARTM product line due to the loss of certain key customers. We recorded a loss related to this exit activity of \$8.6 million in the nine months ended September 30, 2016. This loss includes \$5.3 million for the write off of inventory and associated disposal costs and \$3.2 million for the write off of fixed assets. Disposition of Joint Venture

In May 2016, as the result of a legal settlement with our joint venture partner BASF, S.A., we dissolved our joint venture in Paulinia, Brazil. As part of the settlement, we obtained 100% interests in the joint venture and the real estate, building, and other assets of the joint venture located at our Paulinia manufacturing facility. In accordance with ASC 323-10-35 Dissolution of a Joint Venture, we recorded a gain of \$3.2 million during the nine months ended September 30, 2016 for the fair market value of these assets less the carrying value of our investment in the joint venture.

Sale of Belpre Compounding Unit

On January 29, 2016, we sold certain assets including intellectual property, inventory, equipment, and other intangible assets associated with our Belpre, Ohio, compounding unit (the "BCU") for total proceeds of \$72.8 million, of which \$72.0 million was used to pay down existing indebtedness during the first quarter of 2016. The BCU is used to manufacture HSBC and USBC based compounds. We recognized a gain on the sale of \$45.4 million during the nine months ended September 30, 2016. In connection with the sale, we entered into an exclusive polymer supply agreement with a seven year term and a compound manufacturing agreement for a transition period of up to two years with the purchaser. Our historical compound sales have primarily been directed into personal care, protective film, consumer, medical and automotive applications, with the compound sales primarily reported under the Specialty Polymers product group.

5. Share-Based Compensation

We account for share-based awards under the provisions of ASC 718, Compensation—Stock Compensation. Accordingly, share-based compensation cost is measured at the grant date based on the fair value of the award and we expense these costs using the straight-line method over the requisite service period. Share-based compensation expense was \$2.1 million and \$2.0 million for the three months ended September 30, 2016 and 2015, respectively, and \$7.3 million and \$6.6 million for the nine months ended September 30, 2016 and 2015, respectively.

SeptemberDecember

6. Detail of Certain Balance Sheet Accounts

	30, 2016	31, 2015
	(In thousa	
Inventories of products:	(
Finished products	\$230,932	\$211,273
Work in progress	4,618	
Raw materials	86,295	
Total inventories of products		\$264,107
Intangible assets:		
Contractual agreements	\$261,051	\$ —
Technology	145,965	45,553
Customer relationships	60,207	35,145
Tradenames/trademarks	77,390	26,562
Software	42,324	34,435
Intangible assets	586,937	141,695
Less accumulated amortization:		
Contractual agreements	16,421	_
Technology	42,825	35,833
Customer relationships	31,031	28,170
Tradenames/trademarks	23,880	18,819
Software	21,204	17,271
Total accumulated amortization	135,361	100,093
Intangible assets, net of accumulated amortization	\$451,576	\$41,602
Other payables and accruals:		
Employee related	\$31,240	\$23,850
Interest payable	40,176	8,004
Arizona Chemical transaction accrual	_	18,267
Property, plant, and equipment accruals	24,352	16,142
Other	61,562	24,748
Total other payables and accruals	\$157,330	\$91,011
Other long-term liabilities:		
Pension and other post-retirement benefits	\$120,100	\$85,997
Other	21,205	10,995
Total other long-term liabilities	\$141,305	\$96,992

Changes in accumulated other comprehensive loss by component were as follows:

	Cumulative Unrealized Foreign Loss on Currency Cash Flow Translation Hedges	Unrealized Loss on Net Investment Hedges	Benefit Plans Liability, Net of Tax	Total
	(In thousands)			
December 31, 2014	\$(21,870) \$—	\$ (1,926)	\$(75,422)	\$(99,218)
Other comprehensive loss before reclassifications	(38,787) —			(38,787)
Amounts reclassified from accumulated other comprehensive loss		_	_	_
Net other comprehensive loss for the year	(38,787) —	_		(38,787)
September 30, 2015	(60,657) —	(1,926)	(75,422)	(138,005)
December 31, 2015	(65,995) —	(1,926)	(70,647)	(138,568)
Other comprehensive income (loss) before reclassification	s27,311 (5,354)	_		21,957
Amounts reclassified from accumulated other comprehensive income (loss)		_	_	_
Net other comprehensive income (loss) for the year	27,311 (5,354)			21,957
September 30, 2016	\$(38,684) \$(5,354)	\$ (1,926)	\$(70,647)	\$(116,611)

7. Earnings Per Share ("EPS")

Basic EPS is computed by dividing net income attributable to Kraton by the weighted-average number of shares outstanding during the period. Diluted EPS is computed by dividing net income attributable to Kraton by the diluted weighted-average number of shares outstanding during the period and, accordingly, reflects the potential dilution that could occur if securities or other agreements to issue common stock, such as stock options, were exercised, settled or converted into common stock and were dilutive. The diluted weighted-average number of shares used in our diluted EPS calculation is determined using the treasury stock method.

Unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock awards, are considered to be participating securities, and therefore, the two-class method is used for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and is excluded from the calculation of EPS allocated to common stock. Our restricted stock awards are subject to forfeiture and restrictions on transfer until vested and have identical voting, income and distribution rights to the unrestricted common shares outstanding. Our weighted average restricted stock awards outstanding were 653,434 and 558,431 for the three months ended September 30, 2016 and 2015, respectively, and 671,722 and 553,400 for the nine months ended September 30, 2016 and 2015, respectively, to satisfy employee payroll tax withholding requirements and none withheld during the three months ended September 30, 2016 and 2015, respectively. We immediately retired all shares withheld and the transactions were reflected in additional paid in capital in the Condensed Consolidated Statements of Changes in Equity and as a purchase of treasury stock in the Condensed Consolidated Statements of Cash Flows.

The computation of diluted EPS includes weighted average restricted share units of 172,933 and 143,204 for the three months ended September 30, 2016 and 2015, respectively, and 175,798 for the nine months ended September 30, 2016. The computation of diluted EPS excludes weighted average restricted share units of 133,317 for the nine months ended September 30, 2015, as they are anti-dilutive due to a net loss attributable to Kraton for each period. The computation of diluted EPS includes weighted average performance share units of 32,498 and 32,498 for the three months ended September 30, 2016 and 2015, respectively, and 32,498 for the nine months ended September 30, 2016. The computation of diluted EPS excludes weighted average performance share units of 33,564 for the nine months ended September 30, 2015, as they are anti-dilutive due to a net loss attributable to Kraton for each period. In addition, the computation of diluted EPS also excludes the effect of performance share units for which the performance contingencies had not been met as of the reporting date, amounting to 496,220 for the three and nine months ended September 30, 2016 and 279,328 for the three and nine months ended September 30, 2015. The computation of diluted EPS includes stock options added under the treasury method of 357,303 and 170,602 for the three months ended September 30, 2016 and 2015, respectively, and 212,005 for the nine months ended September 30, 2016. The computation of diluted EPS excludes the effect of the potential exercise of stock options that are anti-dilutive, amounting to 906,954 and 1,472,988 for the three and nine months ended September 30, 2015, respectively.

The calculations of basic and diluted EPS are as follows:

		onths Ended or 30, 2016		Septemb	onths Ended er 30, 2015	
	Net Income Attributat to Kraton	Weighted Average Shares Outstanding	Earnings Per Share	Net Income Attributa to Kraton	Weighted Average blie Shares Outstanding	Earnings Per Share
	(In thousa	ands, except p	er share	data)		
Basic: As reported Amounts allocated to unvested restricted shares	(329)	30,874 (653)		\$8,446 (152)	31,061 (558)	
Amounts available to common stockholders Diluted:	15,231	30,221	\$ 0.50	8,294	30,503	\$ 0.27
Amounts allocated to unvested restricted shares Non participating share units Stock options added under the treasury stock method Amounts reallocated to unvested restricted shares		653 205 357 (653)		152 — — (150)	558 175 171 (558)	
Amounts available to stockholders and assumed conversions	\$15,237	30,783	\$ 0.49	\$8,296	30,849	\$ 0.27
conversions						
	30, 2016 Net Income Attributabl to Kraton	Outstanding	Earnings Per Share	September Net Loss Attributato Kraton	enths Ended er 30, 2015 Weighted blæverage Shares Outstanding	Loss Per Share
	30, 2016 Net Income Attributabl to Kraton	Weighted Average eShares	Earnings Per Share	September Net Loss Attributato Kraton	er 30, 2015 Weighted blæverage Shares	Per Share
Basic: As reported Amounts allocated to unvested restricted shares Amounts available to common stockholders	30, 2016 Net Income Attributabl to Kraton (In thousar \$111,048	Weighted Average eShares Outstanding	Earnings Per Share	Net Loss Attributa to Kraton ata) \$(6,574)	er 30, 2015 Weighted blæverage Shares Outstanding	Per Share
Basic: As reported Amounts allocated to unvested restricted shares Amounts available to common stockholders Diluted: Amounts allocated to unvested restricted shares Non participating share units	30, 2016 Net Income Attributabl to Kraton (In thousar \$111,048 (2,422) 108,626 2,422	Weighted Average eShares Outstanding ids, except per 30,809 (672) 30,137	Earnings Per Share er share da	Net Loss Attributa to Kraton ata) \$(6,574) 116 (6,458)	er 30, 2015 Weighted blæverage Shares Outstanding 31,332 (553)	Per Share
Basic: As reported Amounts allocated to unvested restricted shares Amounts available to common stockholders Diluted: Amounts allocated to unvested restricted shares	30, 2016 Net Income Attributabl to Kraton (In thousar \$111,048 (2,422) 108,626 2,422 —	Weighted Average eShares Outstanding ids, except per 30,809 (672) 30,137	Earnings Per Share er share da	Net Loss Attributa to Kraton ata) \$(6,574) 116 (6,458)	er 30, 2015 Weighted blæverage Shares Outstanding 31,332 (553) 30,779	Per Share

8. Long-Term Debt

Long-term debt consists of the following:

	September 30, 2016				December 31, 2015				
			Debt				Debt		
	Principal	Discount	Issuance	Total	Principal	Premium	Issuance	Total	
			Costs				Costs ⁽¹⁾		
	(In thousands)								
Term Loan	\$1,278,000	\$(35,708)	\$(33,122)	\$1,209,170	\$ —	\$ —	\$(6,000)	\$(6,000)
10.5% Senior Notes	440,000	(16,509)	(17,951)	405,540	_	_	(2,819)	(2,819)
6.75% Senior Notes		_			350,000	651	(4,268)	346,383	
KFPC Loan Agreement	106,128	_	(280)	105,848	76,912	_	(378)	76,534	
Capital lease obligation	1,529	_	_	1,529	1,634	_		1,634	
Total debt	1,825,657	(52,217)	(51,353)	1,722,087	428,546	651	(13,465)	415,732	
Less current portion of total debt	23,135	_	_	23,135	141	_	_	141	
Long-term debt	\$1,802,522	\$(52,217)	\$(51,353)	\$1,698,952	\$428,405	\$ 651	\$(13,465)	\$415,591	1

⁽¹⁾ Prior to the adoption of ASU No. 2015-03, debt issuance costs of \$1.3 million and \$12.1 million were previously recorded in other current assets and debt issuance costs, respectively in the Consolidated Balance Sheet as of December 31, 2015.

Debt Issuance Costs. We capitalize the debt issuance costs related to issuing long-term debt and amortize these costs using the effective interest method, except for costs related to revolving debt, which are amortized using the straight-line method. Amortization of debt issuance costs are recorded as a component of interest expense and the accelerated write-off of debt issuance costs in connection with refinancing activities are recorded as a component of loss on extinguishment of debt. In conjunction with the closing of the Arizona Chemical Acquisition on January 6, 2016, we amended and restated our asset-based revolving credit facility ("ABL Facility") and the debt issuance costs associated with these efforts were recorded within other current assets and debt issuance costs in the accompanying Condensed Consolidated Balance Sheets. We deferred \$61.3 million of debt issuance costs related to the debt financing in conjunction with the Arizona Chemical Acquisition, of which \$8.8 million was deferred in the fourth quarter of 2015, \$1.7 million was carried over from our previous debt issuance costs and \$50.8 million was deferred during the nine months ended September 30, 2016. In connection with our January 2016 refinancing, we charged to interest expense \$5.0 million of unamortized debt issuance costs related to our previously existing indebtedness. We had net debt issuance cost of \$56.3 million as of September 30, 2016, of which \$5.0 million related to our ABL Facility is recorded as an asset (of which \$1.2 million was included in other current assets) and \$51.4 million is recorded as a reduction to long-term debt. We amortized \$1.8 million and \$0.6 million during the three months ended September 30, 2016 and 2015, respectively, and \$5.3 million and \$1.7 million during the nine months ended September 30, 2016 and 2015, respectively.

Senior Secured Term Loan Facility. In January 2016, Kraton Polymers LLC entered into a senior secured term loan facility in an aggregate principal amount equal to \$1,350.0 million that matures on January 6, 2022 (the "Term Loan Facility"). Subject to compliance with certain covenants and other conditions, we have the option to borrow up to \$350.0 million of incremental term loans plus an additional amount subject to a senior secured net leverage ratio. Borrowings under the Term Loan Facility bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (a) an adjusted LIBOR rate (subject to a 1.0% floor) determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for statutory reserve requirements or (b) an alternate base rate (subject to a 2.0% floor) determined by reference to the highest of (1) the prime rate of Credit Suisse AG, (2) the federal funds effective rate plus 0.5% and (3) the one month adjusted LIBOR rate plus 1.0% per annum. In addition, we are required to pay customary agency fees. As of the date of this filing, the effective rate on the Term Loan Facility was 6.0% comprised of the 1.0% LIBOR floor plus a 5.0% applicable margin.

We are required to make scheduled quarterly payments on the Term Loan Facility of 2.5% of the original principal amount per year through the end of the last quarter of 2016 and 5.0% thereafter, with the balance expected to be due and payable in full on January 6, 2022. Voluntary prepayments on the Term Loan Facility may be made without premium or penalty other than customary "breakage" costs with respect to LIBOR loans and other than a 1.0% premium in connection with certain repricing transactions consummated within a certain period of time after the closing of the Term Loan Facility. In the event we have consolidated excess cash flow for any fiscal year, we are required to prepay an amount of borrowings under the Term Loan Facility equal to at least 50.0% of such cash flow by the 90th day after the end of the fiscal year. The prepayment percentage is reduced to 25.0% if our senior secured net leverage ratio is under 2.5:1.0 or 0% if our senior secured net leverage ratio is below 2.0:1.0.

The Term Loan Facility is a senior secured obligation that is guaranteed by Kraton Corporation and each of its wholly-owned domestic subsidiaries. The Term Loan Facility contains a number of customary affirmative and negative covenants. These covenants include a senior secured net leverage ratio which shall not exceed, as of the last day of any fiscal quarter, 4.00:1.00 through March 31, 2017, which will decrease to 3.75:1.00 through March 31, 2018, 3.50:1.00 through March 31, 2019, and 3.25:1.00 thereafter. As of the date of this filing, we were in compliance with the covenants under the Term Loan Facility. The \$72.0 million received from the sale of compounding assets was used to pay down existing indebtedness under the Term Loan Facility. As a result, our next scheduled principal payment is not due until the third quarter of 2017.

10.5% Senior Notes due 2023. Kraton Polymers LLC and its wholly-owned financing subsidiary Kraton Polymers Capital Corporation issued \$440.0 million aggregate principal amount of 10.5% Senior Notes that mature on April 15, 2023 (the "10.5% Senior Notes"). The 10.5% Senior Notes are general unsecured, senior obligations and are unconditionally guaranteed on a senior unsecured basis by each of Kraton Corporation and each of our wholly-owned domestic subsidiaries. We pay interest on the notes at 10.5% per annum, semi-annually in arrears on April 15 and October 15 of each year, and paid the first interest payment on October 14, 2016. Prior to October 15, 2018, we may redeem up to 40.0% of the aggregate principal amount of the 10.5% Senior Notes with the net proceeds of certain equity offerings at a redemption price equal to 110.5% of the principal amount of the 10.5% Senior Notes plus accrued and unpaid interest, if any, to the date of redemption. After October 15, 2018, 2019, 2020, and 2021 and thereafter, we may redeem all or a part of the 10.5% Senior Notes for 107.875%, 105.250%, 102.625%, and 100.0% of the principal amount, respectively.

ABL Facility. In January 2016, we entered into an amended and restated ABL Facility which provides financing of up to \$250.0 million. We did not have any borrowings drawn under this facility as of September 30, 2016. The ABL Facility is primarily secured by receivables and inventory, and borrowing availability under the ABL Facility is subject to borrowing base limitations based on the level of receivables and inventory available for security. Revolver commitments under the ABL Facility consist of U.S. and Dutch revolving credit facility commitments, and the terms of the ABL Facility require the U.S. revolver commitment comprises at least 60.0% of the commitments under the facility.

The ABL Facility provides that we have the right at any time to request up to \$100.0 million of additional commitments under this facility, provided that we satisfy additional conditions described in the credit agreement and provided further that the U.S. revolver commitment comprises at least 60.0% of the commitments after giving effect to such increase. We cannot guarantee that all of the lending counterparties contractually committed to fund a revolving credit draw request will actually fund future requests, although we currently believe that each of the counterparties would meet their funding requirements. The ABL Facility terminates on January 6, 2021; however, we may, from time to time, request that the lenders extend the maturity of their commitments; provided that at no time shall there be more than four different maturity dates under the ABL Facility.

Borrowings under the ABL Facility bear interest at a rate per annum equal to the applicable margin plus (1) a base rate determined by reference to the prime rate of Bank of America, N.A. in the jurisdiction where the currency is being funded or (2) LIBOR for loans that bear interest based on LIBOR. The initial applicable margin for borrowings under the ABL Facility is 0.5% with respect to U.S. base rate borrowings and 1.5% with respect to LIBOR or borrowings made on a European base rate. The applicable margin ranges from 0.5% to 1.0% with respect to U.S. base rate borrowings and 1.5% to 2.0% for LIBOR or borrowings made on a European base rate per annum based on the

average excess availability for the prior fiscal quarter. In addition to paying interest on outstanding principal amounts under the ABL Facility, we are required to pay a commitment fee in respect of the un-utilized commitments at an annual rate of 0.375%.

The ABL Facility contains a financial covenant requiring us to maintain a minimum fixed charge coverage ratio of 1.0 to 1.0 if availability under the ABL facility is below a specified amount. Our failure to comply with this financial covenant would give rise to a default under the ABL Facility. If factors arise that negatively impact our profitability, we may not be able to satisfy this covenant. In addition, the ABL Facility contains customary events of default, including, without limitation, a failure to make payments under the ABL facility, cross-default with respect to other indebtedness and cross-judgment default, certain bankruptcy events and certain change of control events. If we are unable to satisfy the covenants or other provisions of the ABL Facility at any future time, we would need to seek an amendment or waiver of such covenants or other provisions. The respective lenders under the ABL Facility may elect not to consent to any amendment or waiver requests that we may make in the future, and, if they do consent, they may do so on terms that are not favorable to us. In the event that we are unable to obtain any such waiver or amendment and we are not able to refinance or repay the ABL Facility, our inability to meet the covenants or other provisions of the ABL Facility would constitute an event of default, which would permit the bank lenders to accelerate the ABL Facility. Such acceleration may in turn constitute an event of default under the Term Loan Facility, 10.5% Senior Notes or other indebtedness. As of the date of this filing, we were in compliance with the covenants under the ABL Facility.

KFPC Loan Agreement. On July 17, 2014, KFPC executed a syndicated loan agreement (the "KFPC Loan Agreement") in the amount of 5.5 billion New Taiwan Dollars ("NTD"), or \$175.3 million (converted at the September 30, 2016 exchange rate), to provide additional funding to construct the HSBC facility in Taiwan and to provide funding for working capital requirements and/or general corporate purposes.

The KFPC Loan Agreement is comprised of a NTD 4.29 billion Tranche A, or \$136.7 million (converted at the September 30, 2016 exchange rate), to fund KFPC's capital expenditures, and a NTD 1.21 billion Tranche B, or \$38.6 million (converted at the September 30, 2016 exchange rate), to fund working capital requirements and/or general corporate purposes. As of September 30, 2016, NTD 3.3 billion, or \$106.1 million (converted at the September 30, 2016 exchange rate) was drawn on the KFPC Loan Agreement. The facility period of the KFPC Loan Agreement is five years from January 17, 2015 (the first drawdown date). KFPC may continue to draw on the KFPC Loan Agreement for the first 28 months following the first drawdown date. Subject to certain conditions, KFPC can request a two-year extension of the term of the KFPC Loan Agreement.

The total outstanding principal amount is payable in six semi-annual installments with the first payment due on July 17, 2017 and each subsequent payment due every six months thereafter. The first five installments shall be in an amount equal to 10% of the outstanding principal amount and the final installment shall be in an amount equal to the remaining 50% of the outstanding principal amount. In the event the extension period is granted, the final 50% of the outstanding principal amount shall be repaid in five equal semi-annual installments with the first installment due on the original final maturity date.

The KFPC Loan Agreement is subject to a variable interest rate composed of a fixed 0.8% margin plus the three-month or six-month fixing rate of the Taipei Interbank Offered Rate (depending on the interest period selected by KFPC in the drawdown request or the interest period notice), subject to a floor of 1.7%. Interest is payable on a monthly basis. For the three and nine months ended September 30, 2016, our effective interest rate for borrowings on the KFPC Loan Agreement was 1.80%.

The KFPC Loan Agreement contains certain financial covenants that change during the term of the KFPC Loan Agreement. The financial covenants include a maximum debt to equity ratio of 3.0 to 1.0 through 2016, which will decrease to 2.0 to 1.0 in 2017 and 1.2 to 1.0 in 2018; a minimum tangible net worth requirement of \$50.0 million through 2018, which will increase to \$100.0 million in 2019; and a minimum interest coverage ratio of 2.5 to 1.0 commencing at the end of the year of 2016, which will increase to 5.0 to 1.0 at the end of the year of 2017. In each case, these covenants are calculated and tested on an annual basis. Formosa Petrochemical Corporation and Kraton Polymers LLC are the guarantors of the KFPC Loan Agreement with each guarantor guaranteeing 50% of the indebtedness.

Debt Maturities. The remaining principal payments on our outstanding total debt as of September 30, 2016, are as follows:

Principal **Payments** (In thousands) October 1, 2016 through September 30, 2017 \$23,135

\$1,825,657

October 1, 2017 through September 30, 2018 88,882 October 1, 2018 through September 30, 2019 88,892 October 1, 2019 through September 30, 2020 120,741 October 1, 2020 through September 30, 2021 67,688 Thereafter 1,436,319 Total debt

See Note 9 Fair Value Measurements, Financial Instruments, and Credit Risk for fair value information related to our long-term debt.

9. Fair Value Measurements, Financial Instruments, and Credit Risk

ASC 820, "Fair Value Measurements and Disclosures" defines fair value, establishes a consistent framework for measuring fair value and expands disclosure requirements about fair value measurements. ASC 820 requires entities to, among other things, maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.

ASC 820 defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date.

ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect our market assumptions.

In accordance with ASC 820, these two types of inputs have created the following fair value hierarchy:

Level 1—Inputs that are quoted prices (unadjusted) for identical assets or liabilities in active markets;

Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability, including:

Quoted prices for similar assets or liabilities in active markets

Quoted prices for identical or similar assets or liabilities in markets that are not active

Inputs other than quoted prices that are observable for the asset or liability

Inputs that are derived principally from or corroborated by observable market data by correlation or other means; and Level 3—Inputs that are unobservable and reflect our assumptions used in pricing the asset or liability based on the best information available under the circumstances (e.g., internally derived assumptions surrounding the timing and amount of expected cash flows).

Recurring Fair Value Measurements. The following tables set forth by level within the fair value hierarchy our financial assets and liabilities that were accounted for at fair value on a recurring basis as of September 30, 2016 and December 31, 2015. These financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. Our assessment of the significance of a particular input to the fair value measurement requires judgment, which judgment may affect the valuation of their fair value and placement within the fair value hierarchy levels.

Fair Value Measurements at

	Balance Sheet Location	September 1 2016 f	Reporti Quoted Prices n Active	Significant Other SObservable	Significant	
		(In thousan	ds)			
	Other					
Derivative asset – current	current assets Other	\$33	S —	\$ 33	\$	_
Retirement plan asset – noncurren	ntlong-term assets	2,508 2	2,508	_	_	
Derivative liability – current	Other payables and accruals	(2,409) -	_	(2,409)	· —	
Derivative liability – noncurrent	Other long-term liability	(5,620) -		(5,620)	· —	
Total		\$(5,488) \$		Fair Valu Reporting Quoted Prices in Active	\$ e Measurement of Date Using Significant	ents at Significant
	Balance Sh	neet Location	Dece 2015	Markets ember 31, for Identical Assets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)
Retirement plan asset – current Retirement plan asset – noncurren Total	_	-term assets	\$272 1,636 \$1,96	5 1,636 08 \$ 1,908	\$ - \$ -	-\$ — -\$ —
The following table presents the o	carrying valu	ies and appro	oximate		ember 30, 20 ying	
Term Loan (significant other obse	ervable inpu	ts – level 2)		(In the \$1,2)	housands) 278,000 \$1,2	

10.5% Senior Notes (quoted prices in active market for identical assets level 1)				
6.75% Senior Notes (quoted prices in active market for identical assets level 1)	_\$—	\$—	\$350,000	\$350,000
Capital lease obligation (significant other observable inputs – level 2)	\$1,529	\$1,529	\$1,634	\$1,634
KFPC Loan Agreement	\$106,128	\$106,128	\$76,912	\$76,912
26				

Financial Instruments

Interest Rate Swap Agreements. Periodically, we enter into interest rate swap agreements to hedge or otherwise protect against interest rate fluctuation on a portion of our variable rate debt. These interest rate swap agreements are designated as cash flow hedges on our exposure to the variability of future cash flows.

On February 18, 2016, we entered into a series of interest rate swap agreements in an effort to convert a substantial portion of our future interest payments pursuant to the Term Loan Facility to a fixed interest rate. On February 18, 2016, we entered into two interest rate swaps, each with a notional value of \$323.9 million, an effective date of January 3, 2017 and a maturity date of December 31, 2020. We entered into two more interest rate swaps on March 21, 2016, each with a notional value of \$138.8 million, an effective date of January 3, 2017 and a maturity date of December 31, 2020. We recorded an unrealized loss of \$8.0 million in accumulated other comprehensive income (loss) related to the effective portion of these interest rate swap agreements for the nine months ended September 30, 2016.

Foreign Currency Hedges. Periodically, we enter into foreign currency agreements to hedge or otherwise protect against fluctuations in foreign currency exchange rates. These agreements do not qualify for hedge accounting and gains/losses resulting from both the up-front premiums and/or settlement of the hedges at expiration of the agreements are recognized in the period in which they are incurred. For the three months ended September 30, 2016 and 2015, we settled these hedges and recorded a loss of \$0.1 million and a loss of \$1.9 million, respectively, and for the nine months ended September 30, 2016 and 2015, we settled these hedges and recorded a gain of \$1.4 million and a loss of \$5.9 million, respectively, which are recorded in cost of goods sold in the Condensed Consolidated Statements of Operations. These contracts are structured such that these gains/losses from the mark-to-market impact of the hedging instruments materially offset the underlying foreign currency exchange gains/losses to reduce the overall impact of foreign currency exchange movements throughout the period.

On January 6, 2016, we acquired several foreign currency forward contracts from Arizona Chemical, which are used to manage future cash flows with respect to exchange rate fluctuations. One of our subsidiaries, Arizona Chemical BV, a Netherlands based entity with a Euro functional currency, is a party to foreign currency forward contracts to purchase Swedish Krona and United States Dollars to hedge certain intercompany foreign exchange exposures. We have designated both of these forward contracts as a cash flow hedge. These contracts were entered into on various dates beginning in October 2015 through January 6, 2016 with various maturity dates from January 2016 through December 2016. The notional amount of these contracts was EUR 2.1 million or \$1.8 million (converted at the September 30, 2016 exchange rate). We recorded an unrealized loss of \$0.1 million in accumulated other comprehensive income (loss) related to the effective portion of these forward contracts for the nine months ended September 30, 2016.

Credit Risk

The use of derivatives creates exposure to credit risk relating to potential losses that could be recognized in the event that the counterparties to these instruments fail to perform their obligations under the contracts, which we seek to minimize by limiting our counterparties to major financial institutions with acceptable credit ratings and by monitoring the total value of positions with individual counterparties. In the event of a default by one of our counterparties, we may not receive payments provided for under the terms of our derivatives.

We analyze our counterparties' financial condition prior to extending credit and we establish credit limits and monitor the appropriateness of those limits on an ongoing basis. We also obtain cash, letters of credit, or other acceptable forms of security from customers to provide credit support, where appropriate, based on our financial analysis of the customer and the contractual terms and conditions applicable to each transaction.

10. Income Taxes

Income tax expense was \$2.2 million and \$3.1 million for the three months ended September 30, 2016 and 2015, respectively, and income tax benefit was \$83.0 million and income tax expense was \$4.1 million during the nine months ended September 30, 2016 and 2015, respectively. Our effective tax rate was an expense of 12.9% and 27.7% for the three months ended September 30, 2016 and 2015, respectively. Our effective tax rate was a benefit of 316.5% and an expense of 115.5% for the nine months ended September 30, 2016 and 2015, respectively. Our effective tax rates differ from the U.S. corporate statutory tax rate of 35.0%, primarily due to the mix of our pretax income or loss generated in various jurisdictions, permanent items, uncertain tax positions, and changes in our valuation allowances. During the nine months ended September 30, 2016, our pretax earnings in the Netherlands, Sweden, and Finland decreased our effective tax rate due to the statutory rates of 25%, 22%, and 20%, respectively. During the nine months ended September 30, 2015, our pretax earnings in the Netherlands decreased our effective tax rate as the statutory rate is 25% and losses generated in Taiwan increased our effective tax rate as the statutory rate is 17%.

The provision for income taxes differs from the amount computed by applying the U.S. corporate statutory income tax rate to income (loss) before income taxes for the reasons set forth below.

	Three Months Ended		Nine Months Ended		
	Septemb	er 30,	September 30,		
	2016	2015	2016	2015	
	(In thous	sands)			
Income taxes at the statutory rate	\$5,964	\$3,883	\$9,181	\$(1,253)	
State taxes, net of federal benefit	1,114	_	521		
Foreign tax rate differential	(2,436)	(3,628)	(6,018	(3,920)	
Permanent differences	(2,934)	510	(265)	1,547	
Uncertain tax positions	292	178	928	490	
Valuation allowance	176	2,696	(87,404)	8,091	
Return to provision adjustments	33	(521)	33	(483)	
Other	(11)	(41)	_	(337)	
Income tax expense (benefit)	\$2,198	\$3,076	\$(83,024)	\$4,135	
	Three M	onths	Nina Man	the Endad	
	Three M Ended	onths		ths Ended	
			Nine Mon Septembe		
	Ended				
Income taxes at the statutory rate	Ended Septemb 2016	per 30,	September 2016	r 30,	
Income taxes at the statutory rate State taxes, net of federal benefit	Ended Septemb 2016 35.0 %	per 30, 2015	September 2016	r 30, 2015	
· · · · · · · · · · · · · · · · · · ·	Ended Septemb 2016 35.0 %	per 30, 2015	September 2016 35.0 %	r 30, 2015	
State taxes, net of federal benefit	Ended Septemb 2016 35.0 % 6.5	per 30, 2015 35.0 %	September 2016 35.0 % 2.0	2015 35.0 %	
State taxes, net of federal benefit Foreign tax rate differential	Ended Septemb 2016 35.0 % 6.5 (14.3)	per 30, 2015 35.0 % — (32.7)	September 2016 35.0 % 2.0 (22.9)	r 30, 2015 35.0 % — 109.5	
State taxes, net of federal benefit Foreign tax rate differential Permanent differences	Ended Septemb 2016 35.0 % 6.5 (14.3) (17.2)	per 30, 2015 35.0 % — (32.7) 4.6	September 2016 35.0 % 2.0 (22.9) (1.0)	r 30, 2015 35.0 % — 109.5 (43.2)	
State taxes, net of federal benefit Foreign tax rate differential Permanent differences Uncertain tax positions	Ended Septemb 2016 35.0 % 6.5 (14.3) (17.2) 1.7	per 30, 2015 35.0 % — (32.7) 4.6 1.6	September 2016 35.0 % 2.0 (22.9) (1.0) 3.5	r 30, 2015 35.0 % — 109.5 (43.2) (13.7)	
State taxes, net of federal benefit Foreign tax rate differential Permanent differences Uncertain tax positions Valuation allowance	Ended Septemb 2016 35.0 % 6.5 (14.3) (17.2) 1.7 1.0	oer 30, 2015 35.0 % — (32.7) 4.6 1.6 24.3	September 2016 35.0 % 2.0 (22.9) (1.0) 3.5 (333.2)	r 30, 2015 35.0 % — 109.5 (43.2) (13.7) (226.0)	

We record a valuation allowance when it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. As of September 30, 2016 and December 31, 2015, we had recorded a valuation allowance of \$43.9 million and \$100.1 million, respectively, against our net operating loss carryforwards and other deferred tax assets. As part of the Arizona Chemical Acquisition, we reassessed the need for a valuation allowance against our net operating loss deferred tax assets. In our assessment, we consider the level of historical and projected future taxable income expected to be generated. We increased our valuation allowances by \$0.2 million for the three months ended September 30, 2016, primarily related to current period net operating losses. We increased our valuation allowance by \$2.7 million for the three months ended September 30, 2015, primarily related to current period net operating losses in the U.S. tax jurisdiction. During the nine months ended September 30, 2016, we released \$56.2 million of the valuation allowances, of which \$87.4 million primarily related to our U.S. net operating loss carryforwards and other deferred tax assets, partially offset by \$31.2 million of new valuation allowances assumed in connection with the Arizona Chemical Acquisition. We increased our valuation allowances by \$7.0 million for the nine months ended September 30, 2015, which included \$8.1 million related to current period net operating losses, partially offset by a \$1.1 million decrease related to changes in other comprehensive income (loss).

In purchase accounting, we recorded \$61.9 million of deferred taxes on the U.S. parent's inside basis differences of the acquired foreign assets of Arizona Chemical.

As of September 30, 2016 and December 31, 2015, we had total unrecognized tax benefits of \$11.1 million and \$4.3 million, respectively, related to uncertain tax positions, all of which, if recognized, would impact our effective tax rate. During the three months ended September 30, 2016 and 2015, we had a decrease in uncertain foreign tax positions of \$2.5 million and an increase of \$0.2 million, respectively. We had an increase of \$6.8 million during the nine months ended September 30, 2016, primarily related to assumed uncertain tax positions in the United States in connection with the Arizona Chemical Acquisition. We had a \$0.2 million increase to uncertain foreign tax positions during the nine months ended September 30, 2015. We recorded interest and penalties related to unrecognized tax benefits within the provision for income taxes. During the next twelve months we anticipate decreasing our unrecognized tax benefits by \$1.9 million related to certain of our European tax positions as a result of the expiration of the statute of limitations. We are continuing to evaluate the uncertain tax positions assumed in connection with the Arizona Chemical Acquisition.

We file income tax returns in the U.S. federal, state and foreign jurisdictions. For our U.S. federal income tax returns, the statute of limitations has expired through the tax year ended December 31, 2003. As a result of net operating loss carryforwards from 2004, the statute of limitations remains open for all years subsequent to 2003. In addition, open tax years for state and foreign jurisdictions remain subject to examination.

11. Commitments and Contingencies

(a) Lease Commitments

We have entered into various long-term non-cancelable operating leases. Future minimum lease commitments at September 30, 2016 are as follows: 2016—\$7.6 million; 2017—\$21.9 million; 2018—\$15.3 million; 2019—\$12.6 million; 2020—\$10.9 million; and 2021 and thereafter—\$15.3 million.

(b) Legal Proceedings

In connection with the closing of the Arizona Chemical Acquisition on January 6, 2016, we assumed responsibility for an open legal proceeding related to a claim from a former customer of Arizona Chemical. On March 21, 2011, Arizona Chemical received a claim from this former customer relating to an alleged breach of warranty and breach of contract regarding delivery of resin products during the period from 2005 through 2009. In March 2014, the jury returned a verdict against Arizona Chemical for \$70.1 million. In addition, the trial court entered two separate judgments against Arizona Chemical in April 2015 for attorneys' costs and interest. Arizona Chemical has filed appeals with the Florida First District Court of Appeal to dispute all three judgments. On May 20, 2016, the appellate court affirmed the jury's verdict on the merits in the underlying case. On July 18, 2016, the appellate court reversed and remanded the trial court's judgment related to interest. On July 19, 2016, the appellate court affirmed the trial court's judgment related to the attorneys' costs. On August 26, 2016, the parties entered into a Mutual Release and

Settlement Agreement resolving all matters between the parties. The judgment was fully satisfied by the insurance company in accordance with the terms of the agreement. On September 27, 2016, the Florida Supreme Court issued an order voluntarily dismissing all appeals filed in the matter.

We received an initial notice from the tax authorities in Brazil during the fourth quarter of 2012 in connection with tax credits that were generated from the purchase of certain goods which were subsequently applied by us against taxes owed. The tax authorities are currently assessing R\$6.1 million, or \$1.9 million (converted at the September 30, 2016 exchange rate). We have appealed the assertion by the tax authorities in Brazil that the goods purchased were not eligible to earn the credits. While the outcome of this proceeding cannot be predicted with certainty, we do not expect this matter to have a material adverse effect upon our financial position, results of operations or cash flows.

On January 28, 2014, we executed a definitive agreement (the "Combination Agreement") to combine with the SBC operations of Taiwan-based LCY Chemical Corp. ("LCY"). The Combination Agreement called for LCY to contribute its SBC business in exchange for newly issued shares in the combined company, such that our existing stockholders and LCY would each own 50% of the outstanding shares of the combined enterprise.

On June 30, 2014, we notified LCY that our Board of Directors intended to withdraw its recommendation to our stockholders to approve the Combination Agreement unless the parties could agree upon mutually acceptable revised terms to the Combination Agreement. This notice cited the decline in operating results for LCY's SBC business in the first quarter of 2014 and a related decline in forecasted results thereafter, together with the decline in our stock price and negative reactions from our stockholders. Following our notification of our Board's intention to change its recommendation, the parties engaged in discussions to determine whether they could mutually agree to changes to the terms of the Combination Agreement that would enable our Board to continue to recommend that our stockholders approve the Combination Agreement. The parties engaged in numerous discussions subsequent to June 30, 2014 regarding possible revisions to the terms of the Combination Agreement.

On July 31, 2014, an explosion occurred in a pipeline owned by LCY in Kaohsiung, Taiwan, causing substantial property damage and loss of life, and numerous governmental and private investigations and claims have been initiated and asserted against LCY. On August 4, 2014, LCY notified us that it would no longer negotiate, and would not agree to, any revisions to the terms of the Combination Agreement. On August 6, 2014, our Board withdrew its recommendation that our stockholders approve the Combination Agreement. On August 8, 2014, we received notice from LCY that LCY had exercised its right to terminate the Combination Agreement.

The provisions of the Combination Agreement provide for us to pay LCY a \$25.0 million break-up fee upon a termination of the Combination Agreement following a withdrawal of our Board's recommendation, unless an LCY material adverse effect has occurred and is continuing at the time of the withdrawal of our Board's recommendation. In LCY's notice terminating the Combination Agreement, LCY requested payment of such \$25.0 million termination fee. On October 6, 2014, LCY filed a lawsuit against us in connection with our refusal to pay the \$25.0 million termination fee. We believe that the impact upon LCY of the July 31, 2014 explosion in a gas pipeline in Kaohsiung, Taiwan, constitutes an LCY material adverse effect as defined in the Combination Agreement, and we have notified LCY that accordingly we are not obligated to pay the termination fee. On July 23, 2015, LCY's lawsuit was dismissed from the Delaware federal court on jurisdictional grounds. LCY has the right to re-file its suit in Delaware state court. As of the date of this filing, they had not re-filed their suit. While the ultimate resolution of this matter cannot be predicted with certainty, we do not expect any material adverse effect upon our financial position, results of operations or cash flows from the ultimate outcome of this matter.

We and certain of our subsidiaries, from time to time, are parties to various other legal proceedings, claims and disputes that have arisen in the ordinary course of business. These claims may involve significant amounts, some of which would not be covered by insurance. A substantial settlement payment or judgment in excess of our accruals could have a material adverse effect on our financial position, results of operations or cash flows. While the outcome of these proceedings cannot be predicted with certainty, we do not expect any of these existing matters, individually or in the aggregate, to have a material adverse effect upon our financial position, results of operations or cash flows. (c) Asset Retirement Obligations.

The changes in the aggregate carrying amount of our ARO liabilities are as follows:

	Nine Months		
	Ended Se	ptember	
	30,		
	2016	2015	
	(In thousa	unds)	
Beginning balance	\$10,078	\$10,394	
Obligations assumed in Arizona Chemical Acquisition	1,908		
Additional accruals	2,146		
Accretion expense	303	319	
Obligations settled	(3,780)	(25)	

Foreign currency translation, net 138 (306) Ending Balance \$10,793 \$10,382

We assumed \$1.9 million of an ARO liability from Arizona Chemical as of January 6, 2016 associated with the demolition and decommissioning of manufacturing facility assets. For a portion of our ARO liability related to the decommissioning of the coal boilers at our Belpre, Ohio, facility, we have recorded a liability and corresponding receivable of

\$3.8 million and \$3.6 million as of September 30, 2016 and 2015, respectively, pursuant to the indemnity included in the February 2001 separation agreement from Shell Chemicals.

(d) Environmental Obligations.

In connection with the Arizona Chemical Acquisition, we assumed environmental obligations associated with historical site matters. As of September 30, 2016 we have recorded a liability of \$3.1 million and a corresponding receivable of \$3.1 million relating from an indemnification agreement with International Paper, Arizona Chemical's former owner.

There have been no other material changes to our Commitments and Contingencies disclosed in our most recently filed Annual Report on Form 10-K.

12. Employee Benefits

Retirement Plans.

The components of net periodic benefit costs related to pension benefits are as follows:

	Three 1	Months Er	nded Sept	ember 30,	Nine Mo	onths Ende	d Septem	ber 30,
	2016		2015		2016		2015	
	U.S	Non-U.S.	U.S	Non-U.S.	U.S	Non-U.S.	U.S	Non-U.S.
	Plans	Plans	Plans	Plans ⁽¹⁾	Plans	Plans	Plans	Plans ⁽¹⁾
	(In tho	usands)						
Service cost	\$771	\$ 566	\$883	\$ -	\$2,518	\$ 1,642	\$2,648	\$ —
Interest cost	1,828	632	1,620		5,514	2,264	4,860	
Expected return on plan assets	(2,344)	(698)	(2,115)		(7,011)	(2,593)	(6,345)	_
Amortization of prior service cost	648	5	1,060	_	2,048	17	3,180	_
Net periodic benefit cost	\$903	\$ 505	\$1,448	\$ -	\$3,069	\$1,330	\$4,343	\$ —

⁽¹⁾ Prior to the Arizona Chemical Acquisition our non-US plans were immaterial.

We made contributions of \$4.5 million and \$1.1 million to our pension plans in the nine months ended September 30, 2016 and 2015, respectively.

The components of net periodic benefit cost related to other post-retirement benefits are as follows:

	Tillee	;		
	Months		Nine Months	
	Ended		Ended	
	September		Septem	ber 30,
	30,	30,		
	2016	2015	2016	2015
	U.S	U.S	U.S	U.S
	Plans	Plans	Plans	Plans
	(In th	ousand	s)	
Service cost	\$135	\$150	\$405	\$450
Interest cost	350	318	1,050	953
Amortization of prior service cost	153	190	458	570
Net periodic benefit cost	\$638	\$658	\$1,913	\$1,973

13. Industry Segments and Foreign Operations

Historically, we have reported one segment for the manufacturing and marketing of engineered polymers. Commensurate with the acquisition on January 6, 2016, Arizona Chemical became a separate operating segment with our operations managed through two operating segments: (i) Polymer segment and (ii) Chemical segment. In accordance with the provisions of ASC 280, "Segment Reporting," our chief operating decision-maker has been identified as the President and Chief Executive Officer, who reviews operating results to make decisions about allocating resources and assessing performance for the entire company.

- •Polymer Segment. Our Polymer segment is comprised of our SBCs and other engineered polymers business.
- •Chemical Segment. Our Chemical segment is comprised of our pine-based specialty products business.

Our chief operating decision maker uses operating income (loss) as the primary measure of each segment's operating results in order to allocate resources and in assessing the company's performance. In accordance with ASC 280, Segment Reporting, we have presented operating income (loss) for each segment. The following table summarizes our operating results by segment. We currently do not have sales between segments.

	Three Months Ended September 30, 2016			Three Months Ended September 30, 2015		
	Polymer	Chemical (1)	Total	Polymer	Chemica	l Total
	(In thousa	ınds)				
Revenue	\$272,970	\$181,173	\$454,143	\$269,012	\$ -	-\$269,012
Cost of goods sold	195,962	122,925	318,887	201,202	_	201,202
Gross profit	77,008	58,248	135,256	67,810		67,810
Operating expenses:						
Research and development	6,920	2,773	9,693	7,597		7,597
Selling, general, and administrative	26,383	16,386	42,769	26,917		26,917
Depreciation and amortization	14,977	17,000	31,977	16,145		16,145
Operating income	\$28,728	\$22,089	50,817	\$17,151	\$ -	— 17,151
Earnings of unconsolidated joint venture			94			95
Interest expense, net			(33,870)			(6,151)
Income before income taxes			\$17,041			\$11,095

⁽¹⁾ Our Chemical segment operating results were impacted by \$10.8 million of higher depreciation and amortization as a result of purchase accounting adjustments for property, plant, and equipment and intangibles.

	Nine Months Ended September 30, 2016			Nine Months Ended September 30, 2015		
	Polymer	Chemical (1)	Total	Polymer	Chemical	Total
	(In thousa	inds)				
Revenue	\$786,132	\$542,583	\$1,328,715	\$786,349	\$ -	-\$786,349
Cost of goods sold	576,358	391,386	967,744	624,542	_	624,542
Gross profit	209,774	151,197	360,971	161,807		161,807
Operating expenses:						
Research and development	22,008	8,375	30,383	23,345	_	23,345
Selling, general, and administrative	82,631	53,214	135,845	77,488	_	77,488
Depreciation and amortization	45,199	48,714	93,913	46,852	_	46,852
Operating income	\$59,936	\$40,894	100,830	\$14,122	\$ -	-14,122
Disposition and exit of business activities			40,001			
Loss on extinguishment of debt			(13,423)			
Earnings of unconsolidated joint venture			274			273
Interest expense, net			(101,450)			(17,975)
Income (loss) before income taxes			\$26,232			\$(3,580)

⁽¹⁾ Our Chemical segment operating results were impacted by \$24.7 million of amortization of step-up to fair market value of their inventories, and \$30.4 million of higher depreciation and amortization as a result of purchase accounting adjustments for property, plant, and equipment and intangibles.

The following table presents long-lived assets including goodwill and total assets.

	September 30, 2016			December 31, 2015		
	Polymer	Chemical	Total	Polymer	Chemica	l Total
	(In thousands)					
Property, plant, and equipment, net	\$548,911	\$356,206	\$905,117	\$517,673	\$	- \$517,673
Investment in unconsolidated joint venture	\$11,608	\$	\$11,608	\$11,628	\$	-\$11,628
Goodwill	\$ —	\$753,928	\$753,928	\$ —	\$	_\$_
Total assets	\$1,098,458	\$1,820,235	\$2,918,693	\$1,079,235	\$	_\$1,079,235

For geographic reporting, revenue is attributed to the geographic location in which the customers' facilities are located. Long-lived assets consist primarily of property, plant, and equipment, which are attributed to the geographic location in which they are located and are presented at historical cost.

Following is a summary of revenue by geographic region:

Ended September 30,	Nine Months Ended September 30,			
2016 2015 2016 (In thousands)	2015			

Revenue:

United States	\$177,170	\$87,507	\$508,522	\$249,674
Germany	43,782	32,485	132,068	92,188
All other countries	233,191	149,020	688,125	444,487

\$454,143 \$269,012 \$1,328,715 \$786,349

Following is a summary of long-lived assets by geographic region:

September 3 December 31, 2016 2015

(In thousands)

Long-lived assets, at cost:

United States	\$780,582	\$ 497,653
Taiwan	166,840	135,410
France	125,615	112,767
Brazil	73,925	56,344
Germany	64,511	56,292
All other countries	114,551	41,364
	\$1,326,024	\$ 899,830

Our capital expenditures for the Polymer segment, excluding capital expenditures by the KFPC joint venture, were \$35.4 million and \$42.4 million during the nine months ended September 30, 2016 and 2015, respectively, and capital expenditures for our Chemical segment were \$27.5 million during the nine months ended September 30, 2016.

14. Related Party Transactions

We own a 50% equity investment in a SBC manufacturing joint venture in Kashima, Japan. Our due to related party liability on the Condensed Consolidated Balance Sheets is related to this joint venture and purchases from the joint venture amounted to \$8.3 million and \$7.6 million for the three months ended September 30, 2016 and 2015, respectively, and \$22.2 million and \$22.4 million for the nine months ended September 30, 2016 and 2015, respectively.

We own a 50% variable interest in KFPC, a HSBC manufacturing joint venture in Mailiao, Taiwan. The KFPC joint venture is fully consolidated in our financial statements, and our joint venture partner, Formosa Petrochemical Corporation ("FPCC"), is a related party affiliate. Under the terms of the joint venture agreement, FPCC is to provide certain site services and raw materials to KFPC. Charges from and amounts due to FPCC are immaterial through the period ended September 30, 2016. See Note 15 Variable Interest Entity, for further discussion related to the KFPC joint venture.

In 2015, one of our board members was appointed the Chief Executive Officer of Jacobs Engineering Group, Inc. ("Jacobs") which has historically supplied site maintenance and engineering services for our Belpre, Ohio, facility. Our total purchases from Jacobs during the three and nine months ended September 30, 2016 were \$3.4 million and \$8.5 million, respectively, and our outstanding payable was \$1.0 million as of September 30, 2016.

15. Variable Interest Entity

We hold a variable interest in a joint venture with FPCC to build, own and operate a 30 kiloton HSBC plant at FPCC's petrochemical site in Mailiao, Taiwan. Kraton and FPCC are each 50% owners of the joint venture company, KFPC. Under the provisions of an offtake agreement with KFPC, we have exclusive rights to purchase all production from KFPC. Additionally, the agreement requires us to purchase a minimum of eighty percent of the plant production capacity each year at a defined fixed margin. This offtake agreement represents a variable interest which provides us the power to direct the most significant activities of KFPC and exposes us to the economic variability of the joint venture. As such, we have determined that we are the primary beneficiary of this variable interest entity; and therefore, we have consolidated KFPC in our financial statements and reflected FPCC's 50% ownership as a noncontrolling interest.

The following table summarizes the carrying amounts of assets and liabilities as of September 30, 2016 and December 31, 2015 for KFPC before intercompany eliminations. See Note 8 Long-Term Debt, for further discussion related to the KFPC Loan Agreement executed on July 17, 2014.

C		•
	September	rDecember
	30, 2016	31, 2015
	(In thousa	nds)
Cash and cash equivalents	\$8,793	\$9,315
Other current assets	11,460	6,922
Property, plant, and equipment, net	166,547	135,230
Intangible assets	9,649	9,203
Other long-term assets	1,873	1,424
Total assets	\$198,322	\$162,094
Current liabilities	\$34,982	\$17,057
Long-term debt	95,235	76,534
Total liabilities	\$130,217	\$93,591

16. Supplemental Guarantor Information

Kraton Polymers LLC and its wholly-owned financing subsidiary, Kraton Polymers Capital Corporation (together, the "Issuers"), issued \$440.0 million aggregate principal amount of 10.5% Senior Notes. The 10.5% Senior Notes are general unsecured, senior obligations of the Issuers and are unconditionally guaranteed on a senior unsecured basis by Kraton Corporation and each of its wholly-owned domestic subsidiaries, excluding the Issuers. We do not believe that

separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING BALANCE SHEET

September 30, 2016

(Unaudited)

(In thousands, except par value)

ASSETS Current assets: Cash and cash equivalents Receivables, net of allowances
Cash and cash equivalents \$— \$21 \$22,161 \$121,366 \$— \$143,548 Receivables, net of allowances — 692 93,267 115,908 — 209,867 Inventories of products — 1,203 176,063 144,579 — 321,845 Inventories of materials and supplies — 6,539 27,302 34,293 — 68,134 Other current assets — 8,455 331,473 424,183 — 764,111 Property, plant, and equipment, less accumulated depreciation — 28,935 520,132 356,050 — 905,117 Goodwill — — 753,176 752 — 753,928 Intangible assets, less accumulated amortization — 34,052 383,720 33,804 — 451,576 Investment in consolidated subsidiaries — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income ta
Receivables, net of allowances — 692 93,267 115,908 — 209,867 Inventories of products — 1,203 176,063 144,579 — 321,845 Inventories of materials and supplies — 12,680 8,037 — 20,717 Other current assets — 6,539 27,302 34,293 — 68,134 Total current assets — 8,455 331,473 424,183 — 764,111 Property, plant, and equipment, less accumulated depreciation — 753,176 752 — 753,928 Intangible assets, less accumulated amortization — 34,052 383,720 33,804 — 451,576 Investment in consolidated joint venture — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 30,744 27,994 76,946 (162,352 23,332 Total assets — 80,7
Inventories of products
Inventories of materials and supplies
supplies — 12,680 8,037 — 20,717 Other current assets — 6,539 27,302 34,293 — 68,134 Total current assets — 8,455 331,473 424,183 — 764,111 Property, plant, and equipment, less accumulated depreciation — 28,935 520,132 356,050 — 905,117 Goodwill — — 753,176 752 — 753,928 Intangible assets, less accumulated amortization — 34,052 383,720 33,804 — 451,576 Investment in consolidated subsidiaries 617,286 2,936,770 — — (3,554,056)) — Investment in unconsolidated joint venture — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208 5,116 — 5,218 Other long-term assets — 80,744
Other current assets — 6,539 27,302 34,293 — 68,134 Total current assets — 8,455 331,473 424,183 — 764,111 Property, plant, and equipment, less accumulated depreciation — 28,935 520,132 356,050 — 905,117 Goodwill — — 753,176 752 — 753,928 Intangible assets, less accumulated amortization — 34,052 383,720 33,804 — 451,576 Investment in consolidated subsidiaries 617,286 2,936,770 — — (3,554,056) — Investment in unconsolidated joint venture — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352 23,332 Total assets <td< td=""></td<>
Total current assets — 8,455 331,473 424,183 — 764,111 Property, plant, and equipment, less accumulated depreciation — 28,935 520,132 356,050 — 905,117 Goodwill — — 753,176 752 — 753,928 Intangible assets, less accumulated amortization — 34,052 383,720 33,804 — 451,576 Investment in consolidated subsidiaries 617,286 2,936,770 — — (3,554,056) — Investment in unconsolidated joint venture — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352 23,332 Total assets \$617,286 \$3,090,079 \$2,020,090 \$907,646 \$(3,716,408) \$2,918,693 LIAB
Property, plant, and equipment, less accumulated depreciation — 28,935 520,132 356,050 — 905,117 Goodwill — — 753,176 752 — 753,928 Intangible assets, less accumulated amortization — 34,052 383,720 33,804 — 451,576 Investment in consolidated subsidiaries 617,286 2,936,770 — — (3,554,056) — Investment in unconsolidated joint venture — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208) 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$617,286 \$3,090,079 \$2,020,090 \$907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current portion of long-term debt \$— \$12,374 \$148 \$10,613
accumulated depreciation — 28,935 \$20,132 \$356,050 — 905,117 Goodwill — — 753,176 752 — 753,928 Intangible assets, less accumulated amortization — 34,052 383,720 33,804 — 451,576 Investment in consolidated subsidiaries — 813 — — (3,554,056) — Investment in unconsolidated joint venture — 813 — — 10,795 — — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208) 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$617,286 \$3,090,079 \$2,020,090 \$907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: — \$12,374 \$148 \$10,613 \$—
Intangible assets, less accumulated amortization — 34,052 383,720 33,804 — 451,576 Investment in consolidated subsidiaries 617,286 2,936,770 — — (3,554,056)) — Investment in unconsolidated joint venture — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208) 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$ 617,286 \$3,090,079 \$2,020,090 \$907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$— \$12,374 \$148 \$10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997
amortization Investment in consolidated subsidiaries Investment in unconsolidated joint venture Debt issuance costs — 310,795 — 11,608 Deferred income taxes — 310 Other long-term assets — 80,744 — 27,994 — 76,946 — 3,803 — 5,218 Total assets — \$617,286 — \$3,090,079 — \$2,020,090 — \$907,646 — \$(162,352 —) 23,332 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt — \$12,374 — \$148 — \$10,613 — \$23,135 Accounts payable-trade — 3,364 — 64,210 — 66,986 — 134,560 Other payables and accruals — 52,997 — 45,092 — 59,241 — 157,330 Due to related party — — 14,907 — 14,907
Investment in consolidated subsidiaries Investment in unconsolidated joint venture Debt issuance costs —
subsidiaries 617,286 2,936,770 — — (3,534,056) — Investment in unconsolidated joint venture — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208) 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$ 617,286 \$3,090,079 \$2,020,090 \$ 907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$ — \$12,374 \$148 \$10,613 \$ — \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — — 14,907 — 14,907
Investment in unconsolidated joint venture Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208) 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$ 617,286 \$3,090,079 \$2,020,090 \$907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$ — \$12,374 \$148 \$10,613 \$ — \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — 14,907 — 14,907
venture — 813 — 10,795 — 11,608 Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208) 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$ 617,286 \$3,090,079 \$2,020,090 \$ 907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$— \$12,374 \$148 \$10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — — 14,907 — 14,907
Debt issuance costs — — 3,803 — — 3,803 Deferred income taxes — 310 (208) 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$ 617,286 \$3,090,079 \$2,020,090 \$ 907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$— \$12,374 \$148 \$ 10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — — 14,907 — 14,907
Deferred income taxes — 310 (208) 5,116 — 5,218 Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$ 617,286 \$3,090,079 \$2,020,090 \$ 907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$— \$12,374 \$148 \$10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — — 14,907 — 14,907
Other long-term assets — 80,744 27,994 76,946 (162,352) 23,332 Total assets \$ 617,286 \$3,090,079 \$2,020,090 \$ 907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$— \$12,374 \$148 \$10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — — 14,907 — 14,907
Total assets \$ 617,286 \$3,090,079 \$2,020,090 \$ 907,646 \$(3,716,408) \$2,918,693 LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$— \$12,374 \$148 \$10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — — 14,907 — 14,907
LIABILITIES AND STOCKHOLDERS' AND MEMBER'S EQUITY Current liabilities: Current portion of long-term debt \$— \$12,374 \$148 \$ 10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — 14,907 — 14,907
Current liabilities: \$12,374 \$148 \$10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — 14,907 — 14,907
Current portion of long-term debt \$— \$12,374 \$148 \$10,613 \$— \$23,135 Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — 14,907 — 14,907
Accounts payable-trade — 3,364 64,210 66,986 — 134,560 Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — 14,907 — 14,907
Other payables and accruals — 52,997 45,092 59,241 — 157,330 Due to related party — — 14,907 — 14,907
* •
Total current liabilities — 68,735 109,450 151,747 — 329,932
Long-term debt, net of current — 1,602,336 1,381 95,235 — 1,698,952
portion
Deferred income taxes — (84,031) 287,723 10,084 — 213,776
Litigation payable — — — — — — — — — — — — — — — — — — —
Other long-term liabilities — 894,807 (709,509) 118,359 (162,352) 141,305
Total liabilities — 2,481,847 (310,955) 375,425 (162,352) 2,383,965
Commitments and contingencies (note 11)
Stockholders' and member's equity:
Preferred stock, \$0.01 par value; — — — — — — — — —
100,000 shares authorized;

Edgar Filing: Kraton Corp - Form 10-Q

309	_	_	_	_	309
358,798				_	358,798
	617,286	2,392,774	543,996	(3,554,056)	_
258,179				_	258,179
_	(9,054)	(61,729)	(45,828)		(116,611)
617,286	608,232	2,331,045	498,168	(3,554,056)	500,675
_			34,053	_	34,053
617,286	608,232	2,331,045	532,221	(3,554,056)	534,728
\$ 617,286	\$3,090,079	\$2,020,090	\$ 907,646	\$(3,716,408)	\$2,918,693
	358,798 — 258,179 — 617,286 — 617,286	358,798 — 617,286 258,179 — (9,054) 617,286 608,232 — 617,286 608,232	358,798 — — — 617,286 2,392,774 258,179 — — — (9,054) (61,729 617,286 608,232 2,331,045 — — — 617,286 608,232 2,331,045	358,798 — — — — 617,286 2,392,774 543,996 258,179 — — — — (9,054) (61,729) (45,828) 617,286 608,232 2,331,045 498,168 — — 34,053 617,286 608,232 2,331,045 532,221	358,798 — — — — — — 617,286 2,392,774 543,996 (3,554,056)) 258,179 — — — — — (9,054)) (61,729)) (45,828)) — 617,286 608,232 2,331,045 498,168 (3,554,056) — — 34,053 — 617,286 608,232 2,331,045 532,221 (3,554,056)

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING BALANCE SHEET

December 31, 2015

(In thousands, except par value)

(in thousands, except par value)	Kraton Corporation	Kraton Polymers	Guarantor Subsidiaries	Non-Guaranto Subsidiaries	or Eliminations	Consolidated
ASSETS		LLC				
Current assets:						
Cash and cash equivalents	\$ <i>-</i>	\$7,256	\$11,595	\$ 51,198	\$ —	\$70,049
Receivables, net of allowances		470	37,758	66,861		105,089
Inventories of products		(2,077)	149,200	116,984		264,107
Inventories of materials and			9,880	2,258		12,138
supplies			9,000	2,236		12,136
Other current assets	_	3,594	4,594	21,768	_	29,956
Total current assets		9,243	213,027	259,069		481,339
Property, plant, and equipment,		35,923	256,663	225,087		517,673
less accumulated depreciation	_	35,523	220,003	223,007		317,073
Intangible assets, less accumulated	l	38,721	2,053	828	_	41,602
amortization		, .	,			,
Investment in consolidated	497,308	1,446,567	_		(1,943,875)	
subsidiaries					,	
Investment in unconsolidated joint	<u> </u>	813	_	10,815	_	11,628
venture Debt issuance costs		226	721	390		1,337
Deferred income taxes		320	721	3,547	_	3,867
Other long-term assets	_	28,314	658,253	105,444	(770,222)	21,789
Total assets	 \$ 497,308	\$1,560,127		\$ 605,180	\$(2,714,097)	
LIABILITIES AND STOCKHOL	•			ψ 005,100	ψ(2,714,077)	Ψ1,077,233
Current liabilities:	DENS THE	WIEWIEEK S	LQCIII			
Current portion of long-term debt	\$ —	\$ —	\$141	\$ <i>—</i>	\$ —	\$141
Accounts payable-trade	<u>. </u>	2,030	25,450	31,857	<u> </u>	59,337
Other payables and accruals		45,717	14,983	30,311	_	91,011
Due to related party		_	_	14,101	_	14,101
Total current liabilities		47,747	40,574	76,269	_	164,590
Long-term debt, net of current		337,560	1,493	76,538		415,591
portion		337,300	1,493	70,338	_	413,391
Deferred income taxes		6,334		2,736		9,070
Other long-term liabilities		674,939	88,758	103,517		96,992
Total liabilities		1,066,580	130,825	259,060	(770,222)	686,243
Commitments and contingencies						
(note 11)						
Stockholders' and member's equit	y:					
Preferred stock, \$.01 par value;						
100,000 shares authorized; none						
issued						
Common stock, \$.01 par value;	306	_			_	306
500,000 shares authorized Additional paid in capital	349,871					349,871
Additional paid in capital	J47,0/I	_		_	_	J47,0/I

Member's equity		497,308	1,061,621	384,946	(1,943,875)) —
Retained earnings	147,131					147,131
Accumulated other comprehensive loss	e	(3,761	(61,729) (73,078) —	(138,568)
Kraton Corporation stockholders' and member's equity	497,308	493,547	999,892	311,868	(1,943,875	358,740
Noncontrolling interest	_			34,252	_	34,252
Total stockholders' and member's equity	497,308	493,547	999,892	346,120	(1,943,875	392,992
Total liabilities and stockholders' and member's equity	\$ 497,308	\$1,560,127	\$1,130,717	\$ 605,180	\$(2,714,097)	\$1,079,235

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2016 (Unaudited) (In thousands)

	Kraton Corporation	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiaries	Non-Guarante Subsidiaries	or Elimination	ıs Consolidate	d
Revenue	\$ —	\$ —	\$227,916	\$ 268,179	\$ (41,952	\$454,143	
Cost of goods sold		(2,090)	150,426	212,503	(41,952	318,887	
Gross profit	_	2,090	77,490	55,676		135,256	
Operating expenses:							
Research and development		1,011	2,432	6,250		9,693	
Selling, general, and administrative		(32,042)	24,230	50,581		42,769	
Depreciation and amortization		5,610	21,492	4,875		31,977	
Operating income (loss)		27,511	29,336	(6,030)		50,817	
Earnings in consolidated subsidiaries	14,843	21,259	_	_	(36,102) —	
Earnings of unconsolidated joint venture	_	_		94	_	94	
Interest income (expense), net		(34,163)	(60)	353		(33,870)
Income (loss) before income taxes	14,843	14,607	29,276	(5,583)	(36,102) 17,041	
Income tax benefit (expense)	_	236	288	(2,722)		(2,198)
Consolidated net income (loss)	14,843	14,843	29,564	(8,305)	(36,102) 14,843	
Net loss attributable to noncontrolling interest	_	_	_	717	_	717	
Net income (loss) attributable to Krator	n \$ 14,843	\$14,843	\$ 29,564	\$ (7,588)	\$ (36,102	\$ 15,560	

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Three Months Ended September 30, 2015 (Unaudited) (In thousands)

	Kraton Corporation	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiaries	Non-Guaranto Subsidiaries	or Elimination	ns Consolidated
Revenue	\$ —	\$ <i>—</i>	\$ 140,767	\$ 167,777	\$ (39,532) \$ 269,012
Cost of goods sold		2,814	113,186	124,734	(39,532) 201,202
Gross profit (loss)	_	(2,814)	27,581	43,043		67,810
Operating expenses:						
Research and development	_	1,713	1,128	4,756	_	7,597
Selling, general, and administrative	_	3,445	7,639	15,833	_	26,917
Depreciation and amortization	_	5,652	7,882	2,611	_	16,145
Operating income (loss)	_	(13,624)	10,932	19,843	_	17,151
Earnings in consolidated subsidiaries	8,019	27,684	_	_	(35,703) —
Earnings of unconsolidated joint venture	_	_	_	95	_	95
Interest income (expense), net	_	(6,159)	(101)	109		(6,151)
Income before income taxes	8,019	7,901	10,831	20,047	(35,703) 11,095
Income tax benefit (expense)	_	118		(3,194)		(3,076)
Consolidated net income	8,019	8,019	10,831	16,853	(35,703	8,019
Net loss attributable to noncontrolling interest	_	_	_	427	_	427
Net income attributable to Kraton	\$ 8,019	\$ 8,019	\$ 10,831	\$ 17,280	\$ (35,703	\$ 8,446

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2016 (Unaudited) (In thousands)

	Kraton Corporation	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiaries	Non-Guaranto Subsidiaries	or Eliminations	Consolidated
Revenue	\$ —	\$ —	\$658,995	\$ 788,826	\$(119,106)	\$1,328,715
Cost of goods sold		(1,519)	462,311	626,058	(119,106)	967,744
Gross profit		1,519	196,684	162,768	_	360,971
Operating expenses:						
Research and development		2,196	7,864	20,323		30,383
Selling, general, and administrative		(33,164)	72,297	96,712		135,845
Depreciation and amortization		16,811	63,626	13,476		93,913
Operating income		15,676	52,897	32,257	_	100,830
Disposition and exit of business activities	_		36,821	3,180		40,001
Loss on extinguishment of debt		(13,423)				(13,423)
Earnings in consolidated subsidiaries	109,256	121,262	_	_	(230,518)	_
Earnings of unconsolidated joint venture	_	_	_	274		274
Interest income (expense), net		(101,521)	(952)	1,023		(101,450)
Income before income taxes	109,256	21,994	88,766	36,734	(230,518)	26,232
Income tax benefit (expense)		87,262	(2,071)	(2,167)		83,024
Consolidated net income	109,256	109,256	86,695	34,567	(230,518)	109,256
Net loss attributable to noncontrolling interest	_			1,792		1,792
Net income attributable to Kraton	\$ 109,256	\$109,256	\$ 86,695	\$ 36,359	\$(230,518)	\$111,048

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF OPERATIONS Nine Months Ended September 30, 2015 (Unaudited) (In thousands)

	Kraton Corporation	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiaries	Non-Guaranto Subsidiaries	or Elimination	ns Consolida	ted
Revenue	\$ —	\$ —	\$ 426,787	\$ 489,124	\$(129,562) \$ 786,349	
Cost of goods sold		13,680	352,599	387,825	(129,562) 624,542	
Gross profit (loss)		(13,680)	74,188	101,299		161,807	
Operating expenses:							
Research and development		2,906	2,993	17,446		23,345	
Selling, general, and administrative		(3,090)	30,200	50,378		77,488	
Depreciation and amortization		16,897	21,863	8,092		46,852	
Operating income (loss)		(30,393)	19,132	25,383		14,122	
Earnings (loss) in consolidated subsidiaries	(7,715)	41,329	_	_	(33,614) —	
Earnings of unconsolidated joint venture	_	_	_	273	_	273	
Interest income (expense), net		(18,581)	372	234	_	(17,975)
Income (loss) before income taxes	(7,715)	(7,645)	19,504	25,890	(33,614) (3,580)
Income tax benefit (expense)		(70)	527	(4,592)	_	(4,135)
Consolidated net income (loss)	(7,715)	(7,715)	20,031	21,298	(33,614) (7,715)
Net loss attributable to noncontrolling interest	_	_	_	1,141	_	1,141	
Net income (loss) attributable to Krator	n\$ (7,715)	\$(7,715)	\$ 20,031	\$ 22,439	\$(33,614	\$ (6,574))

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) Three Months Ended September 30, 2016 (Unaudited) (In thousands)

	Kraton Corporation	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiarie	Non-Guara s Subsidiarie	intor Elimination es	s Consolida	ated
Net income (loss) attributable to Kraton	\$ 14,843	\$14,843	\$ 29,564	\$ (7,588) \$ (36,102)	\$ 15,560	
Other comprehensive income (loss):							
Foreign currency translation adjustments, net of tax	_	_	_	3,994	_	3,994	
Unrealized loss on cash flow hedges, net of tax benefit of \$27	f	(21)	_	(27) —	(48)
Other comprehensive income (loss), net of tax	_	(21)	_	3,967	_	3,946	
Comprehensive income (loss) attributable to Kraton	14,843	14,822	29,564	(3,621) (36,102)	19,506	
Comprehensive income attributable to noncontrolling interest	_	_	_	339	_	339	
Consolidated comprehensive income (loss)	\$ 14,843	\$14,822	\$ 29,564	\$ (3,282) \$(36,102)	\$ 19,845	

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) Three Months Ended September 30, 2015 (Unaudited) (In thousands)

	Kraton Corporatio	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiarie	Non-Guara s Subsidiarie	ntor Elimination s	s Consolida	ated
Net income attributable to Kraton	\$ 8,019	\$ 8,019	\$ 10,831	\$ 17,280	\$ (35,703)	\$ 8,446	
Other comprehensive income:							
Foreign currency translation adjustments, net of tax of \$0	_	(75)	_	(14,897) —	(14,972)
Other comprehensive loss, net of tax	_	(75)		(14,897) —	(14,972)
Comprehensive income attributable to Kraton	8,019	7,944	10,831	2,383	(35,703)	(6,526)
Comprehensive loss attributable to noncontrolling interest	_		_	(2,717) —	(2,717)
Consolidated comprehensive income (loss)	\$ 8,019	\$ 7,944	\$ 10,831	\$ (334) \$(35,703)	\$ (9,243)

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) Nine Months Ended September 30, 2016 (Unaudited) (In thousands)

	Kraton Corporation	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiarie	Non-Guarant s Subsidiaries	tor Eliminations	s Consolidat	ted
Net income attributable to Kraton	\$ 109,256	\$109,256	\$ 86,695	\$ 36,359	\$(230,518)	\$111,048	
Other comprehensive income:							
Foreign currency translation	_		_	27,311	_	27,311	
adjustments, net of tax				- 7-		- ,-	
Unrealized loss on cash flow hedges, new of tax benefit of \$2,737	<u> </u>	(5,293)		(61)	_	(5,354)
Other comprehensive income (loss), net		(5,293)		27,250		21,957	
of tax		(3,293)		27,230		21,937	
Comprehensive income attributable to	109,256	103,963	86,695	63,609	(230,518)	133,005	
Kraton	107,230	103,703	00,025	03,007	(230,310)	133,003	
Comprehensive loss attributable to noncontrolling interest	_		_	(199)	_	(199)
Consolidated comprehensive income	\$ 109,256	\$103,963	\$ 86,695	\$ 63,410	\$(230,518)	\$ 132,806	

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME (LOSS) Nine Months Ended September 30, 2015 (Unaudited) (In thousands)

	Kraton Corporati	ion	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiarie	Non-Guaran s Subsidiaries	tor Elimination	s Consolida	ted
Net income (loss) attributable to Kraton	\$ (7,715)	\$(7,715)	\$ 20,031	\$ 22,439	\$ (33,614)	\$ (6,574)
Other comprehensive income (loss):								
Foreign currency translation adjustments, net of tax of \$0	_		148	_	(38,935) —	(38,787)
Other comprehensive income (loss), net of tax	f		148	_	(38,935) —	(38,787)
Comprehensive income (loss) attributable to Kraton	(7,715)	(7,567)	20,031	(16,496) (33,614)	(45,361)
Comprehensive loss attributable to noncontrolling interest	_		_	_	(2,579) —	(2,579)
Consolidated comprehensive income (loss)	\$ (7,715)	\$(7,567)	\$ 20,031	\$ (19,075	\$ (33,614)	\$ (47,940)

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Nine Months Ended September 30, 2016 (Unaudited) (In thousands)

	Kraton Corporation	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiaries	Non-Guaranto Subsidiaries	Eliminatio	on Consolidated
Cash flows provided by (used in) operating activities	⁵ \$ —	\$(53,043)	\$142,718	\$ 36,454	\$ —	\$ 126,129
Cash flows provided by (used in) investing activities:						
Proceeds from intercompany loans		167,868			(167,8)68	_
Kraton purchase of property, plant and equipment	_	(2,253)	(38,082)	(22,550)	_	(62,885)
KFPC purchase of property, plant and equipment	_	_	_	(16,995)	_	(16,995)
Purchase of software and other intangibles		(3,280)	(1,411)			(4,691)
Acquisition, net of cash acquired	_	(1,367,08)		43,393	_	(1,312,105)
Sale of assets	—	_	72,803	_	_	72,803
Net cash provided by (used in) investing activities	_	(1,204,753)	44,900	3,848	(167,8)68	(1,323,873)
Cash flows provided by financing						
activities:						
Proceeds from debt		1,732,890	50.075			1 702 065
			•			1,782,965
Repayments of debt		(430,058)	•	_	_	(480,133)
Repayments of debt KFPC proceeds from debt	_		•			(480,133) 24,368
Repayments of debt KFPC proceeds from debt Capital lease payments	_ _ _		•			(480,133) 24,368 (105)
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock		(430,058) — —	(50,075)		_ _ _ _	(480,133) 24,368
Repayments of debt KFPC proceeds from debt Capital lease payments		(430,058) — — —	(50,075)			(480,133) 24,368 (105)
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock		(430,058) — —	(50,075) — (105) —			(480,133) 24,368 (105)
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock Cash contributions from member	<u>(1,658)</u>	(430,058) — — — — (967)	(50,075) — (105) —			(480,133) 24,368 (105)
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock Cash contributions from member Cash distributions to member	<u>(1,658)</u>	(430,058) — — — — (967)	(50,075) — (105) —			(480,133) 24,368 (105) (967)
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock Cash contributions from member Cash distributions to member Proceeds from the exercise of stock options	<u>(1,658)</u>	(430,058) — — (967) 2,625 —	(50,075) — (105) — — — — — (5,155) (3,717)	24,368 — — — — —	(967) — —	(480,133) 24,368 (105) (967) — 2,625
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock Cash contributions from member Cash distributions to member Proceeds from the exercise of stock options Settlement of interest rate swap	<u>(1,658)</u>	(430,058) — — (967) 2,625 —	(50,075) — (105) — — — — — (5,155) (3,717)			(480,133) 24,368 (105) (967) — 2,625 (5,155)
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock Cash contributions from member Cash distributions to member Proceeds from the exercise of stock options Settlement of interest rate swap Debt issuance costs Payments on intercompany loans Net cash provided by financing activities	(1,658) s 2,625 — —	(430,058) — — (967) 2,625 —	(50,075) — (105) — — — — (5,155) (3,717) (168,075)	24,368 — — — — — — — — — — — 207 24,575	(967) — —	(480,133) 24,368 (105) (967) — 2,625 (5,155)
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock Cash contributions from member Cash distributions to member Proceeds from the exercise of stock options Settlement of interest rate swap Debt issuance costs Payments on intercompany loans	(1,658) s 2,625 — —	(430,058) — — (967) 2,625 — (53,929) —	(50,075) — (105) — — — — (5,155) (3,717) (168,075)	24,368 — — — — — — — — — — — — —	(967) — — — — 167,868	(480,133) 24,368 (105) (967) — 2,625 (5,155) (57,646) —
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock Cash contributions from member Cash distributions to member Proceeds from the exercise of stock options Settlement of interest rate swap Debt issuance costs Payments on intercompany loans Net cash provided by financing activities	(1,658) s 2,625 — —	(430,058) — (967) 2,625 — (53,929) — 1,250,561 —	(50,075) — (105) — — — — (5,155) (3,717) (168,075)	24,368 — — — — — — — — — — — 207 24,575	(967) — — — — 167,868	(480,133) 24,368 (105) (967) — 2,625 (5,155) (57,646) — 1,265,952
Repayments of debt KFPC proceeds from debt Capital lease payments Purchase of treasury stock Cash contributions from member Cash distributions to member Proceeds from the exercise of stock options Settlement of interest rate swap Debt issuance costs Payments on intercompany loans Net cash provided by financing activities Effect of exchange rate differences on cash Net increase (decrease) in cash and cash	(1,658) s 2,625 — —	(430,058) — — (967) 2,625 — — (53,929) — 1,250,561 —	(50,075) — (105) — — — — (5,155) (3,717) (168,075) (177,052) —	24,368 — — — — — — — — — — — 207	(967) — — — — 167,868	(480,133) 24,368 (105) (967) — 2,625 (5,155) (57,646) — 1,265,952 5,291

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

KRATON CORPORATION CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS Nine Months Ended September 30, 2015 (Unaudited) (In thousands)

	Kraton Corporation	Kraton Polymers LLC ⁽¹⁾	Guarantor Subsidiari	Non-Guara es Subsidiario	antor Eliminat es	ion Consolidated
Cash flows provided by (used in) operating activities	\$ —	\$(16,074)	\$ 73,706	\$ 23,941	\$ —	\$ 81,573
Cash flows provided by (used in) investing activities:						
Proceeds from intercompany loans		48,927	_	_	(48,927	_
Kraton purchase of property, plant, and equipment	_	(913)	(29,257) (12,214) —	(42,384)
KFPC purchase of property, plant, and equipment	_	_	_	(46,097) —	(46,097)
Purchase of software and other intangibles		(1,717)	(46) —	_	(1,763)
Net cash provided by (used in) investing		46,297	(29,303) (58,311) (48,927	(90,244)
activities		. 0,2 /	(=>,000	, (00,011) (10,52)	(>0,=)
Cash flows provided by (used in) financing						
activities: Proceeds from debt			20.000			20,000
Repayments of debt			30,000 (30,000	_		30,000 (30,000)
KFPC proceeds from debt	_	_	(30,000	55,622	_	(30,000) 55,622
Capital lease payments			— (99)		(99)
Purchase of treasury stock	(31,89)		(99	<i>)</i> —	_	(31,891)
Cash contributions from member	(31,07)	(31,891)	_		31,891	(51,671)
Cash distributions to member	30,869	1,022			(31,89)	
Proceeds from the exercise of stock options	*		_	_	_	1,022
Payments on intercompany loans			(48,927) —	48,927	
Net cash provided by (used in) financing		(20.060.)	•	, 55.600		24.654
activities		(30,869)	(49,026) 55,622	48,927	24,654
Effect of exchange rate differences on cash		_	_	(6,002) —	(6,002)
Net increase (decrease) in cash and cash equivalents	_	(646)	(4,623) 15,250	_	9,981
Cash and cash equivalents, beginning of period	_	646	5,881	47,291	_	53,818
Cash and cash equivalents, end of period	\$ —	\$ —	\$ 1,258	\$ 62,541	\$ —	\$ 63,799

The Issuers are co-issuers of the 10.5% Senior Notes that mature on April 15, 2023. Kraton Polymers Capital Corporation has minimal assets and income. We do not believe that separate financial statements and other disclosures concerning the guarantors (other than Kraton Corporation) would provide any additional information that would be material to investors in making an investment decision.

17. Subsequent Events

We have evaluated events and transactions that occurred after the balance sheet date and determined that there were no significant events or transactions that would require recognition or disclosure in our condensed consolidated financial statements for the period ended September 30, 2016.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.

INTRODUCTION

You should read the following discussion of our financial condition and results of operations with our audited consolidated financial statements and related notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. This discussion contains forward-looking statements and involves numerous risks, assumptions, and uncertainties, including, but not limited to, the risk factors discussed in the "Risk Factors" section of our most recent Form 10-K, as well as in "Factors Affecting Our Results of Operations," "Risk Factors" and elsewhere in this Form 10-Q. Actual results may differ materially from those contained in any forward-looking statements.

OVERVIEW

We are a leading global specialty chemicals company that manufactures styrenic block copolymers ("SBCs") and other engineered polymers. Effective with the January 6, 2016 acquisition of Arizona Chemical (the "Arizona Chemical Acquisition"), we are now also a leading global producer of value-added specialty products primarily derived from pine wood pulping co-products. Historically, we have reported one segment for the manufacturing and marketing of SBC's and engineered polymers. Commensurate with the Arizona Chemical Acquisition, Arizona Chemical became a separate operating segment and since such date our operations have been managed through two operating segments: (i) Polymer segment and (ii) Chemical segment. Operating results for Arizona Chemical are included in the accompanying condensed consolidated financial statements since the date of acquisition. Polymer Segment

SBCs are highly-engineered synthetic elastomers, which we invented and commercialized over 50 years ago. We developed the first unhydrogenated styrenic block copolymers ("USBC") in 1964 and the first hydrogenated styrenic block copolymers ("HSBC") in the late 1960s. Our SBCs enhance the performance of numerous products by imparting greater flexibility, resilience, strength, durability, and processability, and are used in a wide range of applications, including adhesives, coatings, consumer and personal care products, sealants, lubricants, medical, packaging, automotive, paving, roofing and footwear products. We also sell isoprene rubber ("IR") and isoprene rubber latex ("IRL") which are non-SBC products primarily used in applications such as medical products, personal care, adhesives, tackifiers, paints, and coatings.

Our polymers are typically formulated or compounded with other products to achieve improved, customer-specific performance characteristics in a variety of applications. We seek to maximize the value of our product portfolio by emphasizing complex or specialized polymers and innovations that yield higher margins than more commoditized products. We sometimes refer to these complex or specialized polymers or innovations as being more "differentiated." Our products are found in many everyday applications, including personal care products, such as disposable diapers, and in the rubberized grips of toothbrushes, razor blades and power tools. Our products are also used to impart tack and shear properties in a wide variety of adhesive products and to impart characteristics such as flexibility and durability in sealants and corrosion resistance in coatings. Our paving and roofing applications provide durability, extending road and roof life.

We also produce CariflexTM isoprene rubber and isoprene rubber latex. Our Cariflex products are based on synthetic polyisoprene polymer and do not contain natural rubber latex or other natural rubber products making them an ideal substitute for natural rubber latex, particularly in applications with high purity requirements such as medical, healthcare, personal care, and food contact. We believe the versatility of Cariflex provides opportunities for new, differentiated applications.

We have a portfolio of innovations at various stages of development and commercialization, including polyvinyl chloride alternatives for and medical applications;

polymers and compounds for soft skin and coated fabric applications for transportation and consumer markets; high melt flow polymers for compounding and adhesives formulation; and

synthetic cement formulations and polymers used for viscosity modification in oilfield applications.

Chemical Segment

We manufacture and sell high value products primarily derived from pine wood pulping co-products. We refine and further upgrade two primary feedstocks, crude tall oil ("CTO") and crude sulfate turpentine ("CST"), both of which are co-products of the wood pulping process, into value-added specialty chemicals. We refine CTO through a distillation process into four primary constituent fractions: tall oil fatty acids ("TOFA"), tall oil rosin ("TOR"), distilled tall oil ("DTO"), and tall oil pitch ("Pitch"). We further upgrade TOFA, TOR and DTO into derivatives including dimer acids, polyamide resins, rosin resins, dispersions, and disproportionated resins. We refine CST into terpene fractions, which can be further upgraded into terpene resins. The various fractions and derivatives resulting from our CTO and CST refining process provide for distinct functionalities and properties, determining their respective applications and end markets.

We focus our resources on four target markets: (1) adhesives, (2) roads & construction, (3) tires, and (4) chemical intermediates. Within our target markets, these products are sold into a diverse range of submarkets, including packaging, tapes and labels, pavement marking, high performance tires, fuel additives, oilfield and mining, coatings, metalworking fluids and lubricants, inks, and flavor and fragrances, among others.

While this business is based predominantly on the refining and upgrading of CTO and CST, we have the capacity to use both hydrocarbon-based raw materials, such as alpha-methyl-styrene ("AMS"), rosins and gum rosins where appropriate and, accordingly, are able to offer tailored solutions for our customers.

Our Chemical segment has a portfolio of innovations at various stages of development and commercialization, including:

adhesive tackifiers designed to enable the use of a higher amount of recycled content in packaging materials; high solid adhesive dispersions for labels and tapes that allow for higher coating speeds, which lower process energy costs;

heat stable rheology ink resins that reduce formulation complexity for ink manufacturers while improving ink performance;

high performance tire tread resins that promote wet grip, fuel economy, and tire life;

fuel lubricity improvers that ensure low sulfur targets for diesel fuel can be met;

bitumen additives for the asphalt paving market that enable high recycled content in asphalt mixes; and

insolublemaleic rosin esters used in pavement marking binders that provide thermal oxidation resistance.

Status of Synergies, Operational Improvement, and Cost Reduction Initiatives

We previously announced synergies and operational improvement initiatives associated with the Arizona Chemical Acquisition and a cost reduction initiative targeted at lowering costs in our Polymer segment. Following is a summary of the status of these initiatives:

	Three Months Ended		Nine Months Ended				
	September 30,			September 30,			
	2016	2015	Incremental	2016	2015	Incremental	Cumulative ⁽¹⁾
	(In thous	sands)					
G&A synergies	\$5,099	\$ —	\$ 5,099	\$10,722	\$ —	\$ 10,722	\$ 10,722
Operational improvements	4,224	_	4,224	9,631	_	9,631	9,631
Polymer cost reduction	6,888	5,279	1,609	20,242	11,859	8,383	27,771
	\$16,211	\$5,279	\$ 10,932	\$40,595	\$11,859	\$ 28,736	\$ 48,124

⁽¹⁾ The cumulative Polymer cost reduction initiatives include \$19.4 million realized in the full year 2015.

Belpre Compounding Unit Asset Sale

On January 29, 2016, we sold certain assets including intellectual property, inventory, equipment, and other intangible assets associated with our Belpre, Ohio, compounding unit (the "BCU") for total proceeds of \$72.8 million, of which \$72.0 million was used to pay down existing indebtedness during the first quarter of 2016. The BCU is used to manufacture HSBC and USBC based compounds. We recognized a gain on the sale of \$45.4 million during the nine months ended September 30, 2016. In connection with the sale, we entered into an exclusive polymer supply agreement with a seven year term and a compound manufacturing agreement for a transition period of up to two years with the purchaser. Our historical compound sales have primarily been directed into personal care, protective film, consumer, medical & automotive applications, with the compound sales previously reported under the Specialty Polymers business line. Taking into consideration future polymer sales under the supply agreement, the net revenue impact resulting from the sale of the compounding assets is less than two percent of Kraton's consolidated revenue for the fiscal year ended December 31, 2015.

Factors Affecting Our Results of Operations

International Operations and Currency Fluctuations. We operate a geographically diverse business, serving customers in numerous countries from thirteen manufacturing facilities on four continents. Our sales and production costs are mainly denominated in U.S. dollars, Euro, Japanese Yen, Swedish Krona, and Brazilian Real. From time to time, we use hedging strategies to reduce our exposure to currency fluctuations.

Our financial results are subject to gains and losses on currency translation, which occur when the financial statements of our foreign operations are translated into U.S. dollars. The financial statements of operations outside the United States where the local currency is considered to be the functional currency are translated into U.S. dollars using the exchange rate at each balance sheet date for assets and liabilities and the average exchange rate for each period for revenues, expenses, gains and losses, and cash flows. The effect of translating the balance sheet into U.S. dollars is included as a component of accumulated other comprehensive income (loss). Any appreciation of the functional currencies against the U.S. dollar will increase the U.S. dollar equivalent amounts of revenues, expenses, gains and losses, and cash flows, and any depreciation of the functional currencies will decrease the U.S. dollar amounts reported. Our results of operations are also subject to currency transaction risk. We incur currency transaction risk when we enter into either a purchase or sale transaction using a currency other than the local currency of the transacting entity. The estimated impact from currency fluctuations amounted to pre-tax losses of \$2.4 million and \$0.7 million for the three months ended September 30, 2016 and 2015, respectively, and pre-tax losses of \$5.9 million and \$4.6 million for the nine months ended September 30, 2016 and 2015, respectively.

We generated our revenue from customers located in the following regions:

	Three Mo Ended Sep 30,		Nine Months Ended September 30,		
	2016	2015	2016	2015	
Revenue by Geography:	(In thousa	nds)			
Americas	\$205,157	\$104,483	\$581,458	\$306,744	
Europe, Middle East, and Africa	146,572	91,825	455,277	263,460	
Asia Pacific	102,414	72,704	291,980	216,145	
Total Revenue	\$454,143	\$269,012	\$1,328,715	\$786,349	

Raw Materials. We use butadiene, styrene and isoprene (collectively referred to as "monomers") as our primary raw materials in our Polymer segment and CTO and CST in our Chemical segment. The cost of these raw materials together represented approximately \$130.3 million, or 40.9%, and \$94.1 million, or 46.8%, of our total cost of goods sold for the three months ended September 30, 2016 and 2015, respectively, and \$406.2 million, or 42.0%, and \$297.7 million, or 47.7%, of our total cost of goods sold for the nine months ended September 30, 2016 and 2015, respectively. The cost of these raw materials has generally correlated with changes in energy prices and is generally influenced by supply and demand factors, and for our isoprene monomers the prices of natural and synthetic rubber. Average purchase prices of our raw materials decreased during the three and nine months ended September 30, 2016 compared to the three and nine months ended September 30, 2015.

Seasonality. Seasonal changes and weather conditions typically affect our sales of products in our paving, roadmarking, roofing and construction applications, which generally results in higher sales volumes in the second and third quarters of the calendar year compared to the first and fourth quarters of the calendar year. Sales for our other product applications tend to show relatively little seasonality.

RESULTS OF OPERATIONS

KRATON CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

(In thousands, except per share data)

	Three Months Ended		Nine Months Ended September 30,	
	September 30,		•	
_	2016	2015	2016	2015
Revenue	\$454,143	\$269,012	\$1,328,715	\$786,349
Cost of goods sold	318,887	201,202	967,744	624,542
Gross profit	135,256	67,810	360,971	161,807
Operating expenses:				
Research and development	9,693	7,597	30,383	23,345
Selling, general, and administrative	42,769	26,917	135,845	77,488
Depreciation and amortization	31,977	16,145	93,913	46,852
Operating income	50,817	17,151	100,830	14,122
Disposition and exit of business activities			40,001	_
Loss on extinguishment of debt		_	(13,423)	· —
Earnings of unconsolidated joint venture	94	95	274	273
Interest expense, net	(33,870)	(6,151)	(101,450)	(17,975)
Income (loss) before income taxes	17,041	11,095	26,232	(3,580)
Income tax benefit (expense)	(2,198)	(3,076)	83,024	(4,135)
Consolidated net income (loss)	14,843	8,019	109,256	(7,715)
Net loss attributable to noncontrolling interest	717	427	1,792	1,141
Net income (loss) attributable to Kraton	\$15,560	\$8,446	\$111,048	\$(6,574)
Earnings (loss) per common share:				
Basic	\$0.50	\$0.27	\$3.60	\$(0.21)
Diluted	\$0.49	\$0.27	\$3.56	\$(0.21)
Weighted average common shares outstanding:				
Basic	30,221	30,503	30,137	30,779
Diluted	30,783	30,849	30,557	30,779
Consolidated Desults				

Consolidated Results

Three Months Ended September 30, 2016 compared to Three Months Ended September 30, 2015

Revenue was \$454.1 million for the three months ended September 30, 2016 compared to \$269.0 million for the three months ended September 30, 2015, an increase of \$185.1 million or 68.8%, of which \$181.2 million relates to our Chemical segment.

Cost of goods sold was \$318.9 million for the three months ended September 30, 2016 compared to \$201.2 million for the three months ended September 30, 2015, an increase of \$117.7 million or 58.5%, of which \$122.9 million relates to our Chemical segment. Our Polymer segment cost of goods sold decreased \$5.2 million, largely driven by a \$17.6 million decrease in raw material costs and a \$7.3 million net reduction in other manufacturing costs, partially offset by a \$13.6 million increase related to higher sales volumes and a \$6.1 million negative effect from currency fluctuations. Gross profit was \$135.3 million for the three months ended September 30, 2016 compared to \$67.8 million for the three months ended September 30, 2015, an increase of \$67.4 million or 99.5%, of which \$58.2 million relates to our Chemical segment.

Research and development expenses were \$9.7 million for the three months ended September 30, 2016 compared to \$7.6 million for the three months ended September 30, 2015, an increase of \$2.1 million or 27.6%, of which \$2.8 million relates to our Chemical segment.

Selling, general, and administrative expenses were \$42.8 million for the three months ended September 30, 2016 compared to \$26.9 million for the three months ended September 30, 2015, an increase of \$15.9 million or 58.9%, of which \$16.4 million relates to our Chemical segment.

Depreciation and amortization was \$32.0 million for the three months ended September 30, 2016 compared to \$16.1 million for the three months ended September 30, 2015, an increase of \$15.8 million or 98.1%, of which \$17.0 million relates to our Chemical segment.

Interest expense, net was \$33.9 million for the three months ended September 30, 2016 compared to \$6.2 million for the three months ended September 30, 2015, an increase of \$27.7 million. The increase is primarily due to additional indebtedness related to the Arizona Chemical Acquisition.

Income tax expense was \$2.2 million and \$3.1 million for the three months ended September 30, 2016 and 2015, respectively. Our effective tax rate was an expense of 12.9% and 27.7% for the three months ended September 30, 2016 and 2015, respectively. Our effective tax rates differ from the U.S. corporate statutory tax rate of 35.0% primarily due to the mix of our pretax income or loss generated in foreign jurisdictions, permanent items, uncertain tax positions, and changes in our valuation allowances. For the three months ended September 30, 2016, our pretax earnings in the Netherlands, Sweden, and Finland decreased our effective tax rate due to the local statutory rates of 25%, 22%, and 20%, respectively. During the three months ended September 30, 2015, our pretax earnings in the Netherlands decreased our effective tax rate as the statutory rate is 25% and losses generated in Taiwan increased our effective tax rate as the statutory rate is 17%.

We record a valuation allowance when it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. As of September 30, 2016 and December 31, 2015, we recorded a valuation allowance of \$43.9 million and \$100.1 million, respectively, against our net operating loss carryforwards and other deferred tax assets. We increased our valuation allowances by \$0.2 million for the three months ended September 30, 2016, primarily related to current period net operating losses. We increased our valuation allowance by \$2.7 million for the three months ended September 30, 2015, primarily related to current period net operating losses in the U.S. tax jurisdiction. Net income attributable to Kraton was \$15.6 million or \$0.49 per diluted share for the three months ended September 30, 2016, an increase of \$7.1 million compared to net income of \$8.4 million or \$0.27 per diluted share for the three months ended September 30, 2015. Adjusted earnings per diluted share (non-GAAP) was \$0.63 for the three months ended September 30, 2016 compared to \$0.48 for the three months ended September 30, 2015. See a reconciliation of U.S. generally accepted accounting principles ("GAAP") earnings (loss) per diluted share to non-GAAP adjusted earnings per diluted share below.

Nine Months Ended September 30, 2016 compared to Nine Months Ended September 30, 2015 Our operating results for the nine months ended September 30, 2016 include the operating results for Arizona Chemical since the acquisition date of January 6, 2016.

Revenue was \$1,328.7 million for the nine months ended September 30, 2016 compared to \$786.3 million for the nine months ended September 30, 2015, an increase of \$542.4 million or 69.0%, of which \$542.6 million relates to our Chemical segment.

Cost of goods sold was \$967.7 million for the nine months ended September 30, 2016 compared to \$624.5 million for the nine months ended September 30, 2015, an increase of \$343.2 million or 55.0%, of which \$391.4 million relates to our Chemical segment. Our Chemical segment results include \$24.7 million of higher costs of goods sold related to the fair value adjustment in purchase accounting for inventory, which was fully amortized during the nine months ended September 30, 2016. The Polymer segment cost of goods sold decreased \$48.2 million, largely driven by a \$36.7 million reduction in other manufacturing costs (including a \$5.1 million decrease in turnaround costs), and \$62.1 million decrease in raw material costs, partially offset by a \$43.0 million increase related to higher sales volumes and a \$7.6 million negative effect from currency fluctuations.

Gross profit was \$361.0 million for the nine months ended September 30, 2016 compared to \$161.8 million for the nine months ended September 30, 2015. The increase includes gross profit of \$151.2 million from our Chemical

segment, which includes \$24.7 million of higher costs of goods sold related to the full amortization of the fair value adjustment in purchase accounting for inventory.

Research and development expenses were \$30.4 million for the nine months ended September 30, 2016 compared to \$23.3 million for the nine months ended September 30, 2015, an increase of \$7.0 million or 30.1%, of which \$8.4 million relates to our Chemical segment.

Selling, general, and administrative expenses were \$135.8 million for the nine months ended September 30, 2016 compared to \$77.5 million for the nine months ended September 30, 2015, an increase of \$58.4 million or 75.3%, of which \$53.2 million relates to our Chemical segment.

Depreciation and amortization was \$93.9 million for the nine months ended September 30, 2016 compared to \$46.9 million for the nine months ended September 30, 2015, an increase of \$47.1 million or 100.4%, of which \$48.7 million relates to our Chemical segment.

Disposition and exit of business activities was \$40.0 million for the nine months ended September 30, 2016, which resulted from the exit of our NEXARTM product line and the dissolution of our joint venture in Paulinia, Brazil, and the sale of the BCU.

Loss on extinguishment of debt was \$13.4 million for the nine months ended September 30, 2016, of which \$8.4 million was recognized to satisfy and cancel our previous 6.75% Senior Notes and \$5.0 million was related to the write-off of previously capitalized debt issuance costs, following the Arizona Chemical Acquisition.

Interest expense, net was \$101.5 million for the nine months ended September 30, 2016 compared to \$18.0 million for the nine months ended September 30, 2015, an increase of \$83.5 million. The increase is primarily due to additional indebtedness related to the Arizona Chemical Acquisition.

Income tax benefit was \$83.0 million and income tax expense was \$4.1 million for the nine months ended September 30, 2016 and 2015, respectively. Given the level of our pre-tax book income for the nine months ended September 30, 2016 and the release of a significant portion of our valuation allowance (as further discussed below), our effective tax rate for the nine months ended September 30, 2016 is not meaningful. Our effective tax rate for the nine months ended September 30, 2015 was a 115.5% expense. Our effective tax rates differ from the U.S. corporate statutory tax rate of 35.0% primarily due to the mix of our pretax income or loss generated in foreign jurisdictions, permanent items, uncertain tax positions, and changes in our valuation allowances. For the nine months ended September 30, 2016, our pretax earnings in the Netherlands, Sweden, and Finland decreased our effective tax rate due to the local statutory rates of 25%, 22%, and 20%, respectively. During the nine months ended September 30, 2015, our pretax earnings in the Netherlands decreased our effective tax rate as the statutory rate is 25% and losses generated in Taiwan increased our effective tax rate as the statutory rate is 17%.

We record a valuation allowance when it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. As of September 30, 2016 and December 31, 2015, we recorded a valuation allowance of \$43.9 million and \$100.1 million, respectively, against our net operating loss carryforwards and other deferred tax assets. Following the completion of the Arizona Chemical Acquisition, we reassessed the need for a valuation allowance against our net operating loss deferred tax assets. In our assessment, we consider the level of historical and projected future taxable income expected to be generated. As a result of our assessment, we released \$56.2 million of the valuation allowances, of which \$87.4 million primarily related to our U.S. net operating loss carryforwards and other deferred tax assets, partially offset by \$31.2 million of new valuation allowances assumed in connection with the Arizona Chemical Acquisition.

Net income attributable to Kraton was \$111.0 million or \$3.56 per diluted share for the nine months ended September 30, 2016, an increase of \$117.6 million compared to net loss of \$6.6 million or \$0.21 per diluted share for the nine months ended September 30, 2015. Adjusted earnings per diluted share (non-GAAP) was \$2.07 for the nine months ended September 30, 2016 compared to \$1.26 for the nine months ended September 30, 2015. See a reconciliation of GAAP earnings (loss) per diluted share to non-GAAP adjusted earnings per diluted share below.

Segment Results

Effective with the Arizona Chemical Acquisition our operating segments are as follows:

- •Polymer Segment. Our Polymer segment is comprised of our SBC's and other engineered polymers business.
- •Chemical Segment. Our Chemical segment is comprised of our pine-based specialty products business. Polymer Segment

	Three Months				
	Ended Sep	otember	Nine Months Ended September 30,		
	30,				
	2016	2015	2016	2015	
Revenue	(In thousa	nds)			
Performance Products	\$138,479	\$147,987	\$403,214	\$420,889	
Specialty Polymers	89,107	86,828	256,197	263,082	
Cariflex	45,303	34,044	126,513	102,069	
Other	81	153	208	309	
	\$272,970	\$269,012	\$786,132	\$786,349	
Operating income	\$28,728	\$17,151	\$59,936	\$14,122	
Adjusted EBITDA (non-GAAP)(1)	\$49,576	\$42,393	\$141,023	\$116,773	

Three Months Ended September 30, 2016 compared to Three Months Ended September 30, 2015

Revenue for the Polymer segment was \$273.0 million for the three months ended September 30, 2016 compared to \$269.0 million for the three months ended September 30, 2015, an increase of \$4.0 million or 1.5%. The increase was due to higher sales volumes of \$23.2 million and changes in foreign currency exchange rates of \$3.8 million, partially offset by lower average selling prices amounting to \$23.0 million, which were primarily driven by lower average raw material costs, lower prices for certain SIS product grades and mix. Sales volumes were 85.9 kilotons for the three months ended September 30, 2016, an increase of 5.0 kilotons or 6.1%.

With respect to revenue for the Polymer segment product groups:

CariflexTM revenue was \$45.3 million for the three months ended September 30, 2016 compared to \$34.0 million for the three months ended September 30, 2015. The increase of \$11.3 million was attributable to a 29.4% increase in sales volumes, primarily into surgical glove applications, and changes in foreign currency exchange rates amounting to \$2.4 million.

Specialty Polymers revenue was \$89.1 million for the three months ended September 30, 2016 compared to \$86.8 million for the three months ended September 30, 2015, a \$2.3 million increase, which includes a decrease of \$1.7 million related to the sale of the BCU. The revenue increase was attributable to a 10.2% increase in sales volumes, primarily within automotive and lubricant additive applications, partially offset by lower average selling prices resulting from lower raw material costs.

Performance Products revenue was \$138.5 million for the three months ended September 30, 2016 compared to \$148.0 million for the three months ended September 30, 2015. The \$9.5 million decline was primarily driven by lower average selling prices resulting from lower raw material costs, lower prices for certain SIS product grades reflective of global over capacity for SIS, and product mix, partially offset by a 3.2% increase in sales volumes and changes in foreign currency exchange rates of \$1.1 million. The increase in sales volumes was primarily driven by higher sales into roofing and personal care applications, which more than offset lower sales volumes into paving applications and lower sales of SIS product grades into packaging and industrial adhesive applications. A factor in the decline in paving volume was constrained availability of butadiene arising from a cracker outage from one of our suppliers.

For the three months ended September 30, 2016, the Polymer segment operating income was \$28.7 million compared to \$17.2 million for the three months ended September 30, 2015.

⁽¹⁾ See Non-GAAP reconciliations included below for the reconciliation of each non-GAAP measure to its most directly comparable GAAP measure.

For the three months ended September 30, 2016, the Polymer segment generated Adjusted EBITDA (non-GAAP) of \$49.6 million compared to \$42.4 million for the three months ended September 30, 2015, an increase of \$7.2 million, or 16.9%. The increase was due to higher sales volumes and lower costs, partially offset by modestly lower unit margins, including the

effect of product mix. The effect of currency fluctuations negatively impacted Adjusted EBITDA (non-GAAP) by \$2.2 million. See a reconciliation of GAAP operating income to non-GAAP Adjusted EBITDA below. Nine Months Ended September 30, 2016 compared to Nine Months Ended September 30, 2015 Revenue for the Polymer segment was \$786.1 million for the nine months ended September 30, 2016 compared to \$786.3 million for the nine months ended September 30, 2015. Lower average selling prices amounting to \$76.5 million, primarily driven by lower average raw material costs, lower prices for certain SIS product grades and mix, was offset by an increase of \$74.4 million due to higher sales volumes and changes in foreign currency exchange rates of \$2.0 million. Sales volumes were 250.9 kilotons for the nine months ended September 30, 2016, an increase of 19.3 kilotons or 8.3%.

With respect to revenue for the Polymer segment product groups:

CariflexTM revenue was \$126.5 million for the nine months ended September 30, 2016 compared to \$102.1 million for the nine months ended September 30, 2015. The increase of \$24.4 million was attributable to a 23.7% increase in sales volumes, primarily due to higher sales into surgical glove applications and changes in foreign currency of \$4.1 million, partially offset by a \$4.2 million decrease attributable to lower average selling prices resulting from lower raw material costs.

Specialty Polymers revenue was \$256.2 million for the nine months ended September 30, 2016 compared to \$263.1 million for the nine months ended September 30, 2015, a decrease of \$6.9 million. Excluding the \$7.8 million effect of the sale of the BCU, which occurred in the first quarter of 2016, revenue was essentially unchanged with a 7.2% increase in sales volumes, largely in automotive and industrial applications, offset by lower average selling prices due to lower raw material costs and a \$1.0 million negative effect from changes in currency exchange rates.

Performance Products revenue was \$403.2 million for the nine months ended September 30, 2016 compared to \$420.9 million for the nine months ended September 30, 2015. The \$17.7 million decrease was primarily driven by lower average selling prices resulting from lower raw material costs, lower prices for certain SIS product grades and mix, and changes in foreign currency exchange rates of \$1.2 million, partially offset by a 7.5% increase in sales volumes. The increase in sales volumes was primarily driven by paving, roofing, and personal care applications, partially offset by lower sales of SIS product grades into packaging and industrial adhesive applications.

For the nine months ended September 30, 2016, the Polymer segment operating income was \$59.9 million compared to \$14.1 million for the nine months ended September 30, 2015.

For the nine months ended September 30, 2016, the Polymer segment generated \$141.0 million of Adjusted EBITDA (non-GAAP) compared to \$116.8 million for the nine months ended September 30, 2015, an increase of \$24.3 million or 20.8%. The increase was a result of higher sales volumes and lower costs, partially offset by lower unit margins, including the effect of product mix. The effect of currency fluctuations negatively impacted Adjusted EBITDA (non-GAAP) by \$4.9 million. See a reconciliation of GAAP operating income to non-GAAP Adjusted EBITDA below.

Chemical Segment

under GAAP.

Commensurate with our acquisition on January 6, 2016, Arizona Chemical is a separate operating segment. The following results of operations for the Chemical segment have been included in our consolidated results effective as of the date of the acquisition.

For the
Three period
Months January 6,
Ended 2016
Septemberthrough
30, 2016
September
30, 2016

 Revenue
 (In thousands)

 Adhesives
 \$60,771
 \$186,903

 Roads and construction
 13,778
 40,845

 Tires
 10,380
 30,238

 Chemical intermediates
 96,244
 284,597

 \$181,173
 \$542,583

NON-GAAP FINANCIAL MEASURES

Adjusted Gross Profit, EBITDA, Adjusted EBITDA, and Adjusted Earnings Per Diluted Share We consider Adjusted Gross Profit, EBITDA, Adjusted EBITDA and Adjusted Diluted Earnings Per Share to be important supplemental measures of our performance and believe they are frequently used by investors, securities analysts, and other interested parties in the evaluation of our performance and/or that of other companies in our industry, including period-to-period comparisons. In addition, management uses these measures to evaluate operating performance, and our incentive compensation plan bases incentive compensation payments on our Adjusted EBITDA performance, along with other factors. Adjusted Gross Profit, EBITDA, Adjusted EBITDA, and Adjusted Diluted Earnings Per Share have limitations as analytical tools and in some cases can vary substantially from other measures of our performance. You should not consider any of them in isolation, or as substitutes for analysis of our results

Three Months Nine Months Ended **Ended September** September 30, 30, 2016 2015 2016 2015 (In thousands, except per share amounts) Adjusted Gross Profit⁽¹⁾ (2) \$133,013 \$68,773 \$406,514 \$202,015 EBITDA⁽³⁾ \$82,888 \$33,391 \$221,595 \$61,247 Adjusted EBITDA^{(1) (4)} \$91,074 \$42,393 \$276,911 \$116,773 Adjusted Earnings Per Diluted Share^{(1) (2)} \$0.63 \$0.48 \$2.07 \$1.26

⁽¹⁾ The majority of our consolidated inventory is measured using the FIFO basis of accounting. As part of our pricing strategy, we measure our business performance using the ECRC of our inventory and cost of goods sold. Our ECRC is based on our current expectation of the current cost of our significant raw material inputs. ECRC is developed monthly based on actual market-based contracted rates and spot market purchase rates that are expected to occur in the period. We then adjust the value of the significant raw material inputs and their associated impact to finished goods to the current replacement cost to arrive at an ECRC value for inventory and cost of goods sold. The result of this revaluation from the GAAP carrying value creates the spread between GAAP and ECRC. We maintain our perpetual inventory in our global enterprise resource planning system, where the carrying value of our inventory is determined. With inventory valued under GAAP and ECRC, we then have the ability to report cost of goods sold and therefore Adjusted Gross Profit, Adjusted EBITDA, and Adjusted Earnings Per Diluted Share

under both our GAAP convention and ECRC.

- Adjusted Gross Profit is gross profit net of the impact of the spread between the FIFO basis of accounting and ECRC and net of the impact of items we do not consider indicative of our ongoing operating performance. Similarly, Adjusted Earnings Per Diluted Share is earnings per diluted share net of the impact of the spread between the FIFO basis of accounting and ECRC and net of the impact of items we do not consider indicative of
- (2) our ongoing operating performance. We explain how each adjustment is derived and why we believe it is helpful and appropriate in the reconciliations below. You are encouraged to evaluate each adjustment and the reasons we consider it appropriate for supplemental analysis. As a measure of our performance, Adjusted Gross Profit and Adjusted Earnings Per Diluted Share are limited because they often vary substantially from gross profit and earnings per diluted share calculated in accordance with GAAP.
- (3) EBITDA represents net income before interest, taxes, depreciation and amortization. Limitations for EBITDA as an analytical tool include the following:

EBITDA does not reflect the significant interest expense on our debt;

EBITDA does not reflect the significant depreciation and amortization expense associated with our long-lived assets; EBITDA included herein should not be used for purposes of assessing compliance or non-compliance with financial covenants under our debt agreements. The calculation of EBITDA in the debt agreements includes adjustments, such as extraordinary, non-recurring or one-time charges, proforma cost savings, certain non-cash items, turnaround costs, and other items included in the definition of EBITDA in the debt agreements; and other companies in our industry may calculate EBITDA differently than we do, limiting its usefulness as a

other companies in our industry may calculate EBITDA differently than we do, limiting its usefulness as a comparative measure.

Adjusted EBITDA is EBITDA net of the impact of the spread between the FIFO basis of accounting and ECRC

and net of the impact of items we do not consider indicative of our ongoing operating performance. We explain how each adjustment is derived and why we believe it is helpful and appropriate in the reconciliation below. You are encouraged to evaluate each adjustment and the reasons we consider it appropriate for supplemental analysis. As an analytical tool, Adjusted EBITDA is subject to the limitations applicable to EBITDA described above, as well as the following limitations:

due to volatility in raw material prices, Adjusted EBITDA may, and often does, vary substantially from EBITDA, net income and other performance measures, including net income calculated in accordance with US GAAP; and Adjusted EBITDA may, and often will, vary significantly from EBITDA calculations under the terms of our debt agreements and should not be used for assessing compliance or non-compliance with financial covenants under our debt agreements.

Because of these and other limitations, EBITDA and Adjusted EBITDA should not be considered as a measure of discretionary cash available to us to invest in the growth of our business.

Our presentation of non-GAAP financial measures and the adjustments made therein should not be construed as an inference that our future results will be unaffected by unusual or non-recurring items, and in the future we may incur expenses or charges similar to the adjustments made in the presentation of our non-GAAP financial measures. We compensate for these limitations by relying primarily on our GAAP results and using Adjusted Gross Profit, EBITDA, Adjusted EBITDA, and Adjusted Earnings Per Diluted Share only as supplemental measures. See our

We reconcile Gross Profit to Adjusted Gross Profit as follows:

financial statements included elsewhere in this Form 10-O.

·	Three Months Ended September 30, 2016			Three Months Ended September 30, 2015				
	Polymer (In thousa	Chemical ands)	Total	Polymer	Chemica	al Total		
Gross profit	\$77,008	\$ 58,248	\$135,256	\$67,810	\$	- \$67,810		
Add (deduct):								
Restructuring and other charges (a)	743	8	751	61	_	61		
Production downtime (b)				(146)		(146)		
Non-cash compensation expense	128	_	128	122	_	122		
Spread between FIFO and ECRC	(5,001)	1,879	(3,122)	926		926		
Adjusted gross profit (non-GAAP)	\$72,878	\$60,135	\$133,013	\$68,773	\$	- \$68,773		

⁽a) Severance expenses and other restructuring related charges.

In 2015, the reduction in costs is due to additional insurance recovery related to the Belpre, Ohio, production downtime.

	Nine Mor Septembe		Nine Months Ended September 30, 2015			
	Polymer Chemical Total (In thousands)			Polymer ChemicalTotal		
Gross profit	`	,	\$360,971	\$161,807	\$	-\$161,807
Add (deduct):						
Restructuring and other charges (a)	785	8	793	142	_	142
Effect of purchase price accounting on inventory valuation (b)		24,719	24,719	_	_	_
Production downtime (c)		_	_	(474)	_	(474)
Non-cash compensation expense	436	_	436	396		396
Spread between FIFO and ECRC	5,807	13,788	19,595	40,144		40,144
Adjusted gross profit (non-GAAP)	\$216,802	\$189,712	\$406,514	\$202,015	\$	_\$202,015

⁽a) Severance expenses and other restructuring related charges.

We reconcile consolidated net income (loss) and operating income (loss) to EBITDA and Adjusted EBITDA as follows:

Tollows.	Septembe	onths Ende er 30, 2016 Chemical ands)	 - -	Septembe	onths Ended er 30, 2015 ChemicalTotal		
Net income attributable to Kraton Net loss attributable to noncontrolling interest Consolidated net income Add (deduct):	`	,	\$15,560 (717) 14,843			\$8,446 (427 8,019)
Income tax expense Interest expense, net Earnings of unconsolidated joint venture Operating income Add:	\$28,728	\$ 22,089	2,198 33,870 (94) 50,817	\$17,151	\$ -	3,076 6,151 (95 —17,151)
Depreciation and amortization Earnings of unconsolidated joint venture EBITDA Add (deduct): Transaction, acquisition related costs, restructuring, and	14,977 94 43,799 7,216	17,000 39,089 530	31,977 94 82,888 7,746	16,145 95 33,391 5,501	_ _ _	16,145 95 33,391 5,501	
other costs (a) Production downtime (b) KFPC startup costs (c) Non-cash compensation expense (d) Spread between FIFO and ECRC Adjusted EBITDA				(134) 677 2,032 926 \$42,393	 \$	(134 677 2,032 926 \$42,393)

Charges related to the evaluation of acquisition transactions, severance expenses, and other restructuring related charges, which are primarily recorded in selling, general, and administrative expenses.

⁽b) Higher costs of goods sold for our Chemical segment related to the fair value adjustment in purchase accounting for their inventory.

⁽c) In 2015, the reduction in costs is due to additional insurance recovery related to the Belpre, Ohio, production downtime.

- (b) In 2015, the reduction in costs is due to additional insurance recovery related to the Belpre, Ohio, production downtime, which is primarily recorded in cost of goods sold.
- (c) Startup costs related to the joint venture company, KFPC, which are recorded in selling, general, and administrative expenses.
- For the three months ended September 30, 2016 and 2015, respectively, \$1.9 million and \$1.7 million is recorded
- (d) in selling, general and administrative expenses, \$0.1 million and \$0.2 million is recorded in research and development expenses, and \$0.1 million and \$0.1 million is recorded in cost of goods sold.

30, 2016 30, 2015 Polymer Chemical Total Polymer ChemicalTotal	'4)
·	'4)
	'4)
(In thousands)	4)
Net income (loss) attributable to Kraton \$111,048 \$(6,57)	
Net loss attributable to noncontrolling interest (1,792) (1,141	
Consolidated net income (loss) 109,256 (7,715)
Add (deduct):	
Income tax (benefit) expense (83,024) 4,135	_
Interest expense, net 101,450 17,975	5
Earnings of unconsolidated joint venture (274))
Loss on extinguishment of debt 13,423 —	
Disposition and exit of business activities (40,001)	
Operating income \$59,936 \$40,894 100,830 \$14,122 \$ —14,122	2
Add (deduct):	
Depreciation and amortization 45,199 48,714 93,913 46,852 — 46,852	2
Disposition and exit of business activities 40,001 — 40,001 — — —	
Loss on extinguishment of debt $(13,423)$ — $(13,423)$ — — — —	
Earnings of unconsolidated joint venture 274 — 274 273 — 273	
EBITDA 131,987 89,608 221,595 61,247 — 61,24'	7
Add (deduct):	
Transaction, acquisition related costs, restructuring, and other costs (a) 7,773 27,028 7,297 — 7,297	
Disposition and exit of business activities $(40,001)$ — $(40,001)$ — — —	
Loss on extinguishment of debt 13,423 — 13,423 — — —	
Effect of purchase price accounting on inventory valuation (b) 24,719 24,719 — — —	
Production downtime (c) — — — (343) — (343)
KFPC startup costs (d) 3,280 — 3,280 1,827 — 1,827	
Non-cash compensation expense (e) 7,272 — 7,272 6,601 — 6,601	
Spread between FIFO and ECRC 5,807 13,788 19,595 40,144 — 40,144	1
Adjusted EBITDA \$141,023 \$135,888 \$276,911 \$116,773 \$ —\$116,	773

⁽a) Charges related to the evaluation of acquisition transactions, severance expenses, and other restructuring related charges, which are primarily recorded in selling, general, and administrative expenses.

⁽b) Higher costs of goods sold for our Chemical segment related to the fair value adjustment in purchase accounting for their inventory.

⁽c) In 2015, the reduction in costs is due to additional insurance recovery related to the Belpre, Ohio, production downtime, which is primarily recorded in cost of goods sold.

⁽d) Startup costs related to the joint venture company, KFPC, which are recorded in selling, general, and administrative expenses.

For the nine months ended September 30, 2016 and 2015, respectively, \$6.3 million and \$5.7 million is recorded in (e) selling, general and administrative expenses, \$0.6 million and \$0.5 million is recorded in research and development expenses, and \$0.4 million and \$0.4 million is recorded in cost of goods sold.

We reconcile GAAP Earnings (Loss) Per Diluted Share to Adjusted Earnings Per Diluted Share as follows:

	Three I	Three Months		Ionths
	Ended		Ended	
	Septem	ber 30,	September 30,	
	2016	2015	2016	2015
Earnings (Loss) Per Diluted Share	\$0.49	\$0.27	\$3.56	\$(0.21)
Transaction, acquisition related costs, restructuring, and other costs (a)	0.20	0.18	0.72	0.23
Disposition and exit of business activities	_	_	(0.82)	_
Loss on extinguishment of debt	_	_	0.28	_
Production downtime (b)	_	(0.01)	_	(0.01)
Effect of purchase price accounting on inventory valuation (c)	_	_	0.63	_
KFPC startup costs (d)	0.02	0.01	0.04	0.02
Valuation Allowance (e)	_		(2.77)	_
Spread between FIFO and ECRC	(0.08)	0.03	0.43	1.23
Adjusted Earnings Per Diluted Share (non-GAAP)	\$0.63	\$0.48	\$2.07	\$1.26

⁽a) Charges related to the evaluation of acquisition transactions, severance expenses, and other restructuring related charges which are primarily recorded in selling, general, and administrative expenses.

Critical Accounting Policies

Goodwill and Other Intangible Assets. We record goodwill when the purchase price of an acquired business exceeds the fair value of the net identifiable assets acquired. Goodwill and intangible assets are allocated to the reporting unit level based on the estimated fair value at the date of acquisition.

Goodwill and other indefinite-lived intangible assets are tested for impairment at the reporting unit level annually. Our annual measurement date for testing impairment is October 1st. The impairment test includes a comparison of the carrying value of net assets of our reporting units, including goodwill, with their estimate fair values. If the carrying value exceeds the estimated fair value, an impairment charge is recognized in the period in which the review is performed.

For a discussion of our critical accounting policies and estimates that require the use of significant estimates and judgments, see "Management's Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015.

⁽b) In 2015, the reduction in costs is due to additional insurance recovery related to the Belpre, Ohio, production downtime, which is primarily recorded in cost of goods sold.

⁽c) We had higher costs of goods sold for our Chemical segment related to the fair value adjustment in purchase accounting for their inventory.

⁽d) Startup costs related to the joint venture company, KFPC, which are recorded in selling, general, and administrative expenses.

⁽e) Reduction of income tax valuation allowance related to the assessment of our ability to utilize net operating losses in future periods.

LIQUIDITY AND CAPITAL RESOURCES

Description of the Senior Secured Term Loan Facility

Commensurate with the acquisition of Arizona Chemical, Kraton Polymers LLC entered into a senior secured term loan facility in an aggregate principal amount equal to \$1,350.0 million that matures on January 6, 2022 (the "Term Loan Facility"). Subject to compliance with certain covenants and other conditions, we have the option to borrow up to \$350.0 million of incremental term loans plus an additional amount subject to a senior secured net leverage ratio. Borrowings under the Term Loan Facility bear interest at a rate per annum equal to an applicable margin, plus, at our option, either (a) an adjusted LIBOR rate (subject to a 1.0% floor) determined by reference to the costs of funds for U.S. dollar deposits for the interest period relevant to such borrowing adjusted for statutory reserve requirements or (b) an alternate base rate (subject to a 2.0% floor) determined by reference to the highest of (1) the prime rate of Credit Suisse AG, (2) the federal funds effective rate plus 0.5% and (3) the one month adjusted LIBOR rate plus 1.0% per annum. In addition, we are required to pay customary agency fees. As of the date of this filing, the effective rate on the Term Loan Facility was 6.0% comprised of the 1.0% LIBOR floor plus a 5.0% applicable margin. We are required to make scheduled quarterly payments on the Term Loan Facility of 2.5% of the original principal amount per year through the end of the last quarter of 2016 and 5.0% thereafter, with the balance expected to be due and payable in full on January 6, 2022. Voluntary prepayments on the Term Loan Facility may be made without premium or penalty other than customary "breakage" costs with respect to LIBOR loans and other than a 1.0% premium in connection with certain repricing transactions consummated within a certain period of time after the closing of the Term Loan Facility. In the event we have consolidated excess cash flow for any fiscal year, we are required to prepay an amount of borrowings under the Term Loan Facility equal to at least 50.0% of such cash flow by the 90th day after the end of the fiscal year. The prepayment percentage is reduced to 25.0% if our senior secured net leverage ratio is under 2.5:1.0 or 0% if our senior secured net leverage ratio is below 2.0:1.0.

The Term Loan Facility is a senior secured obligation that is guaranteed by Kraton Corporation and each of our wholly-owned domestic subsidiaries. The Term Loan Facility contains a number of customary affirmative and negative covenants. These covenants include a senior secured net leverage ratio which shall not exceed, as of the last day of any fiscal quarter, 4.00:1.00 through March 31, 2017, which will decrease to 3.75:1.00 through March 31, 2018, 3.50:1.00 through March 31, 2019, and 3.25:1.00 thereafter. As of the date of this filing, we were in compliance with the covenants under the Term Loan Facility. The \$72.0 million received from the sale of the compounding assets was used to pay down existing indebtedness. As a result our next scheduled principal payment under the Term Loan Facility is not due until the third quarter of 2017.

Description of the 10.5% Senior Notes due 2023

Commensurate with the Arizona Chemical Acquisition, Kraton Polymers LLC and its wholly-owned financing subsidiary Kraton Polymers Capital Corporation issued \$440.0 million aggregate principal amount of 10.5% senior notes that mature on April 15, 2023 (the "10.5% Senior Notes"). The 10.5% Senior Notes are general unsecured, senior obligations and are unconditionally guaranteed on a senior unsecured basis by each of Kraton Corporation and each of our wholly-owned domestic subsidiaries. We pay interest on the 10.5% Senior Notes at 10.5% per annum, semi-annually in arrears on April 15 and October 15 of each year, and paid the first interest payment on October 14, 2016. Prior to October 15, 2018, we may redeem up to 40.0% of the aggregate principal amount of the notes with the net proceeds of certain equity offerings at a redemption price equal to 110.5% of the principal amount of the 10.5% Senior Notes plus accrued and unpaid interest, if any, to the date of redemption. After October 15, 2018, 2019, 2020, and 2021 and thereafter, we may redeem all or a part of the 10.5% Senior Notes for 107.875%, 105.250%, 102.625%, and 100.0% of the principal amount, respectively.

Description of the ABL Facility

In January 2016, we entered into an amended and restated asset-based revolving credit facility that provides financing of up to \$250.0 million (the "ABL Facility"). The ABL Facility is primarily secured by receivables and inventory, and borrowing availability under the ABL Facility is subject to borrowing base limitations based on the level of receivables and inventory available for security. Revolver commitments under the ABL Facility consist of U.S. and Dutch revolving credit facility commitments, and the terms of the facility require the U.S. revolver commitment comprises at least 60.0% of the commitments under the ABL Facility.

The ABL Facility provides that we have the right at any time to request up to \$100.0 million of additional commitments under this facility, provided that we satisfy additional conditions described in the credit agreement and provided further that the U.S. revolver commitment comprises at least 60.0% of the commitments after giving effect to such increase. We cannot guarantee that all of the lending counterparties contractually committed to fund a revolving credit draw request will actually fund future requests, although we currently believe that each of the counterparties would meet their funding requirements. The ABL Facility terminates on January 6, 2021; however, we may, from time to time, request that the lenders

extend the maturity of their commitments under the ABL Facility; provided that at no time shall there be more than four different maturity dates under the ABL Facility.

Borrowings under the ABL Facility bear interest at a rate per annum equal to the applicable margin plus (1) a base rate determined by reference to the prime rate of Bank of America, N.A. in the jurisdiction where the currency is being funded or (2) LIBOR for loans that bear interest based on LIBOR. The initial applicable margin for borrowings under the ABL Facility is 0.5% with respect to U.S. base rate borrowings and 1.5% with respect to LIBOR or borrowings made on a European base rate. The applicable margin ranges from 0.5% to 1.0% with respect to U.S. base rate borrowings and 1.5% to 2.0% for LIBOR or borrowings made on a European base rate per annum based on the average excess availability for the prior fiscal quarter. In addition to paying interest on outstanding principal amounts under the ABL Facility, we are required to pay a commitment fee in respect of the unutilized commitments at an annual rate of 0.375%.

The ABL Facility contains a financial covenant requiring us to maintain a minimum fixed charge coverage ratio of 1.0 to 1.0 if availability under the ABL Facility is below a specified amount. Our failure to comply with this financial covenant would give rise to a default under the ABL Facility. If factors arise that negatively impact our profitability, we may not be able to satisfy this covenant. In addition, the ABL Facility contains customary events of default, including, without limitation, a failure to make payments under the ABL Facility, cross-default with respect to other indebtedness and cross-judgment default, certain bankruptcy events and certain change of control events. If we are unable to satisfy the covenants or other provisions of the ABL Facility at any future time, we would need to seek an amendment or waiver of such covenants or other provisions. The respective lenders under the ABL Facility may elect not to consent to any amendment or waiver requests that we may make in the future, and, if they do consent, they may do so on terms that are not favorable to us. In the event that we are unable to obtain any such waiver or amendment and we are not able to refinance or repay the ABL Facility, our inability to meet the covenants or other provisions of the ABL Facility would constitute an event of default, which would permit the bank lenders to accelerate the ABL Facility. Such acceleration may in turn constitute an event of default under the Term Loan Facility, 10.5% Senior Notes or other indebtedness. As of the date of this filing, we were in compliance with the covenants under the ABL Facility.

Description of KFPC Loan Agreement

On July 17, 2014, KFPC executed a syndicated loan agreement (the "KFPC Loan Agreement") in the amount of 5.5 billion New Taiwanese Dollars ("NTD"), or \$175.3 million (converted at the September 30, 2016 exchange rate), to provide additional funding to construct the HSBC facility in Taiwan and to provide funding for working capital requirements and/or general corporate purposes.

The KFPC Loan Agreement is comprised of a NTD 4.29 billion Tranche A, or \$136.7 million (converted at the September 30, 2016 exchange rate), to fund KFPC's capital expenditures, and a NTD 1.21 billion Tranche B, or \$38.6 million (converted at the September 30, 2016 exchange rate), to fund working capital requirements and/or general corporate purposes. As of September 30, 2016, NTD 3.3 billion, or \$106.1 million (converted at the September 30, 2016 exchange rate) was drawn and outstanding on the KFPC Loan Agreement. The facility period of the KFPC Loan Agreement is five years from January 17, 2015 (the first drawdown date). KFPC may continue to draw on the loan agreement for the first 28 months following the first drawdown date. Subject to certain conditions, KFPC can request a two-year extension of the term of the KFPC Loan Agreement.

The total outstanding principal amount is payable in six semi-annual installments with the first payment due on July 17, 2017 and each subsequent payment due every six months thereafter. The first five installments shall be in an amount equal to 10% of the outstanding principal amount and the final installment shall be in an amount equal to the remaining 50% of the outstanding principal amount. In the event the extension period is granted, the final 50% of the outstanding principal amount shall be repaid in five equal semi-annual installments with the first installment due on the original final maturity date.

The KFPC Loan Agreement is subject to a variable interest rate composed of a fixed 0.8% margin plus the three-month or six-month fixing rate of the Taipei Interbank Offered Rate (depending on the interest period selected by KFPC in the drawdown request or the interest period notice), subject to a floor of 1.7%. Interest is payable on a monthly basis.

The KFPC Loan Agreement contains certain financial covenants which change during the term of the KFPC Loan Agreement. The financial covenants include a maximum debt to equity ratio of 3.0 to 1.0 through 2016, which will decrease to 2.0 to 1.0 in 2017 and 1.2 to 1.0 in 2018; a minimum tangible net worth requirement of \$50.0 million through 2018, which will increase to \$100.0 million in 2019; and a minimum interest coverage ratio of 2.5 to 1.0 commencing at the end of the year of 2016, which will increase to 5.0 to 1.0 at the end of the year of 2017. In each case, these covenants are calculated and tested on an annual basis. Formosa Petrochemical Corporation and Kraton Polymers LLC are the guarantors of the KFPC Loan Agreement with each guarantor guaranteeing 50% of the indebtedness. At September 30, 2016, KFPC was in compliance with the covenants under the KFPC Loan Agreement. For additional information regarding our KFPC Loan Agreement, see "KFPC Loan Agreement" in Note 8 Long-Term Debt, which is incorporated herein by reference.

Known Trends and Uncertainties

Kraton Corporation is a holding company without any operations or assets other than the operations of its subsidiaries. Cash flows from operations of our subsidiaries, cash on hand, and available borrowings under the Term Loan Facility and ABL Facility are our principal sources of liquidity.

Based upon current and anticipated levels of operations, we believe that cash flows from operations of our subsidiaries, cash on hand, and borrowings available to us will be sufficient to fund our expected financial obligations, planned capital expenditures, and anticipated liquidity requirements, including working capital requirements, our investment in the KFPC joint venture, debt payments, interest payments, benefit plan contributions, and income tax obligations.

Our cash flows are subject to a number of risks and uncertainties, including, but not limited to, earnings, sensitivities to the cost of raw materials, seasonality, and fluctuations in foreign currency exchange rates. Because feedstock costs generally represent a substantial portion of our cost of goods sold, in periods of rising feedstock costs, we generally consume cash in operating activities due to increases in accounts receivable and inventory costs, partially offset by increased value of accounts payable. Conversely, during periods in which feedstock costs are declining, we generate cash flow from decreases in working capital.

Going forward there can be no assurance that our business will generate sufficient cash flow from operations or that future borrowings will be available under the Term Loan Facility and the ABL Facility (the "Senior Secured Credit Facilities")or any new credit facilities or financing arrangements to fund liquidity needs and enable us to service our indebtedness. As of the date of this filing, our available borrowing capacity under the Senior Secured Credit Facilities was \$197.9 million, with no borrowings. Our available cash and cash equivalents are held in accounts managed by third-party financial institutions and consist of cash invested in interest bearing funds and operating accounts. To date, we have not experienced any losses or lack of access to our invested cash or cash equivalents; however, we cannot provide any assurance that adverse conditions in the financial markets will not impact access to our invested cash and cash equivalents.

We made contributions of \$4.5 million and \$1.1 million to our pension plans during the nine months ended September 30, 2016 and 2015, respectively. Following the close of the Arizona Chemical Acquisition on January 6, 2016, we assumed responsibility for several additional international pension plans and one additional U.S defined benefit pension plan. We expect our total pension plan contributions for the year ended December 31, 2016 to be approximately \$6.9 million. Our pension plan obligations are predicated on a number of factors, the primary ones being the return on our pension plan assets and the discount rate used in deriving our pension obligations. If the investment return on our pension plan assets does not meet or exceed expectations during 2016, and the discount rate decreases from the prior year, higher levels of contributions could be required in 2017 and beyond.

As of September 30, 2016, we had \$121.7 million of cash and short-term investments related to foreign operations that

As of September 30, 2016, we had \$121.7 million of cash and short-term investments related to foreign operations that management asserts are permanently reinvested. As a result of net operating loss carryforwards, management estimates that approximately \$2.4 million of additional cash tax expense would be incurred if this cash were repatriated as a result of the net operating loss carryforwards in the United States.

Turbulence in U.S. and international markets and economies may adversely affect our liquidity and financial condition, the liquidity and financial condition of our customers, and our ability to timely replace maturing liabilities and access the capital markets to meet liquidity needs, resulting in adverse effects on our financial condition and results of operations. However, to date we have been able to access borrowings available to us in amounts sufficient to fund liquidity needs.

Our ability to pay principal and interest on our indebtedness, fund working capital, make anticipated capital expenditures, and fund our investment in the KFPC joint venture depends on our future performance, which is subject to general economic conditions and other factors, some of which are beyond our control. "See Part I, Item 1A. Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 for further discussion. Operating Cash Flows

Net cash provided by operating activities totaled \$126.1 million and \$81.6 million in the nine months ended September 30, 2016 and 2015, respectively. This represents a net increase in operating cash flows of \$44.6 million, which was primarily driven by changes in working capital. The net change in working capital provided cash flows of

- \$22.4 million and \$36.5 million for the nine months ended September 30, 2016 and 2015, respectively. The period-over-period changes are as follows:
- \$8.4 million decrease associated with accounts receivable, due to higher sales volumes and timing of cash receipts from customers;
- \$6.4 million decrease in cash flows associated with inventories of products, materials, and supplies, due to higher raw material costs, partially offset by lower inventory volumes in our Polymer segment; partially offset by

\$0.7 million net increase in cash flows due to the timing of payments of other items, including accounts payable, related party transactions, taxes, and pension costs.

Investing Cash Flows

Net cash used in investing activities totaled \$1,323.9 million for the nine months ended September 30, 2016 and \$90.2 million for the nine months ended September 30, 2015, which includes \$1,312.1 million related to the Arizona Chemical Acquisition, net of cash acquired, partially offset by \$72.8 million cash received from the sale of the BCU. Expected Capital Expenditures

We currently expect 2016 capital expenditures, excluding capital expenditures by the KFPC joint venture and capitalized interest, will be approximately \$85.0 million to \$95.0 million. Included in this estimate is approximately \$20.0 million for projects associated with our cost reset initiative and \$3.4 million for projects to achieve operational synergies related to the integration of Arizona Chemical.

We currently anticipate the total KFPC joint venture project construction cost will be approximately \$180.0 million; of which, 2016 capital expenditures will be approximately \$40.0 million. The project has been funded with a combination of equity and debt financing. From the inception of the project to September 30, 2016, we and FPCC have each made equity investments of \$41.6 million to KFPC. On July 17, 2014, KFPC executed a syndicated loan agreement in the amount of 5.5 billion NTD, or \$175.3 million (converted at the September 30, 2016 exchange rate), to provide the debt portion of the project financing including funding for working capital and/or general corporate purposes. Kraton Polymers LLC and FPCC are guarantors of the KFPC Loan Agreement with each guaranteeing 50% of the indebtedness. See Note 8 Long-Term Debt, for further discussion of the KFPC Loan Agreement. Financing Cash Flows

Our consolidated capital structure as of September 30, 2016 was approximately 21.2% equity, 77.3% debt and 1.4% noncontrolling interest compared to approximately 43.7% equity, 52.1% debt, and 4.2% noncontrolling interest at December 31, 2015.

In connection with the Arizona Chemical Acquisition, we issued a \$1,350.0 million Term Loan Facility and \$440.0 million of 10.5% Senior Notes. In addition, we utilized \$37.1 million of the ABL Facility at closing of the Arizona Chemical Acquisition. We applied a portion of the acquisition-related proceeds to prepay our 6.75% Senior Notes (\$350.0 million principal amount plus fees and expenses of \$8.0 million) and fund \$57.6 million of debt issuance costs

Since the date of the Arizona Chemical Acquisition (excluding borrowings under the KFPC Loan Agreement) we repaid approximately \$109 million of Kraton Corporation indebtedness, while increasing cash on hand (excluding KFPC cash) by approximately \$37 million.

Contractual Commitments

Our contractual obligations are summarized in Part II, Item 7. "Management's Discussion and Analysis of Financial Condition and Results of Operations," in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. Other than our obligations under the Arizona Chemical Acquisition stock purchase agreement, there have been no material changes to the contractual obligation amounts disclosed in our annual report on Form 10-K for the fiscal year ended December 31, 2015.

	Payments Due by Period						
	Total	2016	2017	2018	2019	2020	2021 and beyond
	(In millio	ons)					
Long-term debt obligations	\$1,825.7	\$ —	\$40.1	\$88.9	\$88.9	\$120.7	\$1,487.1
Estimated interest payments on debt	739.1	61.8	132.5	128.8	124.0	118.5	173.5
Operating lease obligations	83.7	7.6	21.9	15.3	12.6	10.9	15.3
Purchase obligations (2) (3)	2,723.7	54.0	214.2	212.1	199.7	200.5	1,843.2
Estimated pension obligations (4) (5)	45.3	1.1	2.5	3.9	5.1	6.2	26.5
Total contractual cash obligations	\$5,417.5	\$124.5	\$411.2	\$449.0	\$430.3	\$456.8	\$3,545.6

⁽¹⁾ This period reflects estimated payment for October 1, 2016 through December 31, 2016.

Included in this line are our estimated minimum purchases required under our KFPC joint venture agreement. Due

- Pursuant to operating agreements with LyondellBasell, we are currently paying the costs incurred by them in
- (3) connection with the operation and maintenance of, and other services related to, our Berre, France, and Wesseling, Germany, facilities. These obligations are not included in this table.
- (4) This includes the future pension contributions for our Polymer segment utilizing the following assumptions: The plan was "frozen" at December 31, 2015;

All assets at December 31, 2015 were moved into a portfolio of high quality bonds whose cash flow matches the expected cash flow of the "frozen" plan. The yield on the portfolio of bonds as of December 31, 2015 is equal to the estimated PPA effective rate at January 1, 2016. Assets were assumed to remain in such portfolio until all obligations of the plan were paid out;

- An estimated Pension Protection Act effective rate as of January 1, 2016 of 4.50%;
- All contributions are made at the latest date allowable by law; and
- All other assumptions as used in the 2015 funding actuarial valuation of the plan are met.

Effective with the January 6, 2016 Arizona Chemical Acquisition, we acquired several defined benefit plans in (5)both U.S. and foreign jurisdictions. The unfunded status of these plans was \$35.1 million as of September 30, 2016 and we expect to contribute \$5.1 million to these plans during the twelve months ending December 31, 2016. Off-Balance Sheet Arrangements

We are not involved in any material off-balance sheet arrangements as of September 30, 2016, other than operating leases.

⁽²⁾ to the indefinite term of this joint venture, we have based our minimum purchases on an assumed 20 year useful life of the facility.

Item 3. Quantitative and Qualitative Disclosures about Market Risk.

For quantitative and qualitative disclosures about market risk, see Part II, Item 7A, "Quantitative and Qualitative Disclosures About Market Risk," in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015. There have been no material changes to the quantitative and qualitative disclosures about market risk disclosed in our Annual Report on Form 10-K for the year ended December 31, 2015. See Note 9 Fair Value Measurements, Financial Instruments and Credit Risk for further discussion.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

An evaluation of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rule 13a-15 under the Securities Exchange Act of 1934) was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. As of September 30, 2016, based upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the design and operation of these disclosure controls and procedures were effective.

Changes in Internal Control Over Financial Reporting

We acquired Arizona Chemical on January 6, 2016 and are currently in the process of integrating Arizona Chemical into our existing internal controls over financial reporting. Except for any changes in internal controls related to the integration of Arizona Chemical and its subsidiaries, there were no changes in our internal control over financial reporting during our three months ended September 30, 2016 which were identified in connection with management's evaluation required by paragraph (d) of Rules 13a-15 and 15d-15 under the Securities Exchange Act of 1934 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings.

We and certain of our subsidiaries, from time to time, are parties to various other legal proceedings, claims, and disputes that have arisen in the ordinary course of business. These claims may involve significant amounts, some of which would not be covered by insurance. A substantial settlement payment or judgment in excess of our accruals could have a material adverse effect on our financial position, results of operations, or cash flows. While the outcome of these proceedings cannot be predicted with certainty, we do not expect any of these existing matters, individually or in the aggregate, to have a material adverse effect upon our financial position, results of operations, or cash flows. In January 2014, our Belpre, Ohio, facility experienced a mechanical equipment failure due to inclement weather that resulted in a release of process solvents into nearby waterways. Applicable authorities were notified, and cleanup activities have been completed. Kraton may be required to pay governmental fines or sanctions in excess of \$100,000 in connection with this event.

For more information regarding legal proceedings, including environmental matters, see Note 11 Commitments and Contingencies to the Condensed Consolidated Financial Statements.

Item 1A. Risk Factors.

Readers of this Quarterly Report on Form 10-Q should carefully consider the risks described in our other reports and filings filed with or furnished to the Securities and Exchange Commission, including our prior and subsequent reports on Forms 10-K, 10-Q and 8-K, in connection with any evaluation of our financial position, results of operations and cash flows

The risks and uncertainties in our most recent Annual Report on Form 10-K, are not the only risks that we face. Additional risks and uncertainties not presently known or those that are currently deemed immaterial may also affect our operations. Any of the risks, uncertainties, events or circumstances described therein could cause our future financial condition, results of operations or cash flows to be adversely affected. There have been no material changes from the risk factors disclosed in our most recent Annual Report on Form 10-K.

Item 6. Exhibits.

Exhibit Number

- Certificate of Amendment to the Certificate of Incorporation of Kraton Corporation (incorporated by
- 3.1 reference to Exhibit 3.1 to Kraton Corporation's Current Report on Form 8-K filed with the SEC on September 14, 2016)
- First Amended and Restated Bylaws of Kraton Corporation (incorporated by reference to Exhibit 3.2 to Kraton Corporation's Current Report on Form 8-K filed with the SEC on September 14, 2016)

 Specimen Stock Certificate of Kraton Corporation's Common Stock, par value \$0.01 per share (incorporated
- 4.1 by reference to Exhibit 4.1 to Kraton Corporation's Current Report on Form 8-K filed with the SEC on September 14, 2016)
- 10.1+* Form of Kraton Corporation Restricted Stock Award Agreement under the Kraton Corporation 2016 Equity and Cash Incentive Plan
- 10.2+* Form of Kraton Corporation Restricted Stock Unit Award Agreement under the Kraton Corporation 2016 Equity and Cash Incentive Plan
- 10.3+* Form of Kraton Corporation Restricted Stock Performance Unit Award Agreement under the Kraton Corporation 2016 Equity and Cash Incentive Plan
- 10.4+* Form of Kraton Corporation Nonqualified Option Award Agreement under the Kraton Corporation 2016 Equity and Cash Incentive Plan
- 31.1* Certification of Chief Executive Officer under Section 302 of Sarbanes—Oxley Act of 2002
- 31.2* Certification of Chief Financial Officer under Section 302 of Sarbanes—Oxley Act of 2002
- 32.1* Certification Pursuant to Section 906 of Sarbanes—Oxley Act of 2002
 The following materials from Kraton Corporation Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2016, formatted in XBRL (eXtensible Business Reporting Language): (i)
 Condensed Consolidated Balance Sheets as of September 30, 2016 and December 31, 2015 (Unaudited), (ii)
 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2016
- and 2015 (Unaudited), (iii) Condensed Consolidated Statements of Comprehensive Income (Loss) for the three and nine months ended September 30, 2016 and 2015 (Unaudited), (iv) Condensed Consolidated Statements of Changes in Equity for the nine months ended September 30, 2016 and 2015 (Unaudited), (v) Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2016 and 2015 (Unaudited) and (vi) Notes to Condensed Consolidated Financial Statements (Unaudited).

^{*}Filed herewith.

⁺Denotes management contract or compensatory plan or arrangement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

KRATON CORPORATION

Date: October 27, 2016/s/ Kevin M. Fogarty Kevin M. Fogarty

President and Chief Executive Officer

Date: October 27, 2016/s/ Stephen E. Tremblay

Stephen E. Tremblay

Executive Vice President and Chief Financial Officer